{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000000", "text": "# NCCN_OvarianCancer_v3.2025", "section": "NCCN_OvarianCancer_v3.2025", "page_from": null, "page_to": null, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "8d512eae543cd7fe621f6436b2fe9067b659bb1f0663b4645959a33686534781"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000001", "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)\nOvarian Cancer\nContinue\nIncluding Fallopian Tube Cancer\nand Primary Peritoneal Cancer\nVersion 3.2025 — July 16, 2025\nNCCN recognizes the importance of clinical trials and encourages participation when applicable and available.\nTrials should be designed to maximize inclusiveness and broad representative enrollment.\nNCCN.org\nNCCN Guidelines for Patients® available at www.nccn.org/patients", "section": "Ovarian Cancer", "page_from": 1, "page_to": 1, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "a93263b1d7d73c6b0a06ae71db56d6a94d0fdddd59471a3b681fc3ebc9aafb94"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000002", "text": "NCCN Guidelines Version 3.2025\nOvarian Cancer\nVersion 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNCCN Guidelines Index\nTable of Contents\nDiscussion\n*Deborah K. Armstrong, MD/Chair Ω †\nJohns Hopkins Kimmel Cancer Center\n*Ronald D. Alvarez, MD, MBA/Vice Chair Ω\nVanderbilt-Ingram Cancer Center\n*Floor J. Backes, MD Ω\nThe Ohio State University Comprehensive\nCancer Center - James Cancer Hospital\nand Solove Research Institute\nLisa Barroilhet, MD Ω\nUniversity of Wisconsin\nCarbone Cancer Center\nKian Behbakht, MD Ω\nUniversity of Colorado Cancer Center\nAndrew Berchuck, MD Ω\nDuke Cancer Institute\n*Lee-may Chen, MD Ω\nUCSF Helen Diller Family\nComprehensive Cancer Center\nJoshua Cohen, MD Ω\nCity of Hope National Medical Center\nMarie DeRosa, RN ¥\n*Eric L. Eisenhauer, MD Ω\nMass General Cancer Center\n*David M. Gershenson, MD Ω\nThe University of Texas\nMD Anderson Cancer Center\n*Heidi J. Gray, MD Ω\nFred Hutchinson Cancer Center\nRachel Grisham, MD Ω\nMemorial Sloan Kettering Cancer Center\nNCCN\nEmily Kovach\nSwathi Ramakrishnan, PhD", "section": "Ovarian Cancer", "page_from": 2, "page_to": 2, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "f508b8082049a912ce9827c3f12950dda3534248c11147582dbfdf17c534be0a"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000003", "text": "MD Anderson Cancer Center\n*Heidi J. Gray, MD Ω\nFred Hutchinson Cancer Center\nRachel Grisham, MD Ω\nMemorial Sloan Kettering Cancer Center\nNCCN\nEmily Kovach\nSwathi Ramakrishnan, PhD\nNCCN Guidelines Panel Disclosures\nΩ Gynecology oncology\n‡ Hematology/\nHematology oncology\nÞ Internal medicine\n† Medical oncology", "section": "Ovarian Cancer", "page_from": 2, "page_to": 2, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "eb60777db5667f2d5cd1d530421f397ed15d8b28c7b66c16a239d004e138e330"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000004", "text": "# Nursing\n≠ Pathology\n¥ Patient advocacy\n* Discussion writing\ncommittee member\nContinue\nArdeshir Hakam, MD ≠\nMoffitt Cancer Center\nAngela Jain, MD †\nFox Chase Cancer Center\nGottfried E. Konecny, MD Ω\nUCLA Jonsson Comprehensive Cancer Center\n*Charles A. Leath III, MD, MSPH Ω\nO'Neal Comprehensive\nCancer Center at UAB\nGary Leiserowitz, MD Ω\nUC Davis Comprehensive Cancer Center\nBabak Litkouhi, MD Ω\nStanford Cancer Institute\n*Joyce Liu, MD, MPH † ‡\nDana-Farber/Brigham and\nWomen’s Cancer Center\nLainie Martin, MD †\nAbramson Cancer Center\nat the University of Pennsylvania\n*Daniela Matei, MD † ‡\nRobert H. Lurie Comprehensive Cancer\nCenter of Northwestern University\nMichael McHale, MD Ω\nUC San Diego Moores Cancer Center\n*David S. Miller, MD Ω\nUT Southwestern Simmons\nComprehensive Cancer Center\nJohn Moroney, MD Ω\nThe UChicago Medicine\nComprehensive Cancer Center\nSanja Percac-Lima, MD, PhD Þ\nMass General Cancer Center\nElena Ratner, MD, MBA Ω\nYale Cancer Center/Smilow Cancer Hospital\nSharon Robertson, MD, MPH Ω\nIndiana University Melvin and Bren Simon\nComprehensive Cancer Center\nKerry Rodabaugh, MD Ω\nFred & Pamela Buffett Cancer Center\nJohn Schorge, MD Ω", "section": "Ovarian Cancer", "page_from": 2, "page_to": 2, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "2293da1634d1a61ff12ac8dacd7b2d65d2baef651aa4383388eb148b40deabde"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000005", "text": "Sharon Robertson, MD, MPH Ω\nIndiana University Melvin and Bren Simon\nComprehensive Cancer Center\nKerry Rodabaugh, MD Ω\nFred & Pamela Buffett Cancer Center\nJohn Schorge, MD Ω\nSt. Jude Children's Research Hospital/The\nUniversity of Tennessee Health Science Center\n*Premal H. Thaker, MD Ω\nSiteman Cancer Center at Barnes-Jewish Hospital\nand Washington University School of Medicine\nShitanshu Uppal, MBBS, MBA Ω\nUniversity of Michigan Rogel Cancer Center\nRoberto Vargas, MD Ω\nCase Comprehensive Cancer Center/\nUniversity Hospitals Seidman Cancer\nCenter and Cleveland Clinic Taussig\nCancer Institute\n*Andrea Wahner Hendrickson, MD †\nMayo Clinic Comprehensive Cancer Center\n*Theresa L. Werner, MD † ‡\nHuntsman Cancer Institute\nat the University of Utah\n*Emese Zsiros, MD, PhD Ω\nRoswell Park Comprehensive Cancer Center\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "Ovarian Cancer", "page_from": 2, "page_to": 2, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "c3a708e2357dadfe82254daf6dc986eee683c8ce3d569bc47cdd92a2ddb41fe1"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000006", "text": "NCCN Guidelines Version 3.2025\nOvarian Cancer\nVersion 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nThe NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to\ntreatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual\nclinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations\nor warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN\nGuidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not\nbe reproduced in any form without the express written permission of NCCN. ©2025.\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nFind an NCCN Member Institution:\nhttps://www.nccn.org/home/member-", "section": "Ovarian Cancer", "page_from": 3, "page_to": 3, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "1b1b07c748eb04b46467f554a618ce6c88ad0fb707203eb964cffbbd5eb11e01"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000007", "text": "be reproduced in any form without the express written permission of NCCN. ©2025.\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nFind an NCCN Member Institution:\nhttps://www.nccn.org/home/member-\ninstitutions.\nNCCN Categories of Evidence and\nConsensus: All recommendations are\ncategory 2A unless otherwise indicated.\nSee NCCN Categories of Evidence\nand Consensus.\nNCCN Categories of Preference:\nAll recommendations are considered\nappropriate.\nSee NCCN Categories of Preference.\nNCCN Ovarian Cancer Panel Members\nSummary of the Guidelines Updates\nEpithelial Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer:\nClinical Presentation, Workup, Clinical Stage, Primary Treatment (OV-1)\nPoor Surgical Candidate or Low Likelihood of Optimal Cytoreduction (OV-2)\nDiagnosis by Previous Surgery: Findings and Primary Treatment (OV-3)\nPathologic Staging, Primary Chemotherapy/Primary Adjuvant Therapy (OV-4)\nPost Primary Treatment: Maintenance Therapy (OV-5)\nMonitoring/Follow-Up, Recurrent Disease (OV-6)\nDisease Status, Therapy for Persistent Disease or Recurrence (OV-7)\nLess Common Ovarian Cancers:\nDiagnosis (LCOC-1)\nCarcinosarcoma (Malignant Mixed Müllerian Tumors) of the Ovary (LCOC-2)", "section": "Ovarian Cancer", "page_from": 3, "page_to": 3, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "71f22147dcf19cbe2c0f310bb9dbcd897ad9b7cb197fc167560b8cc65b92669d"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000008", "text": "Disease Status, Therapy for Persistent Disease or Recurrence (OV-7)\nLess Common Ovarian Cancers:\nDiagnosis (LCOC-1)\nCarcinosarcoma (Malignant Mixed Müllerian Tumors) of the Ovary (LCOC-2)\nClear Cell Carcinoma of the Ovary (LCOC-3)\nMucinous Neoplasms of the Ovary (LCOC-4)\nGrade 1 Endometrioid Carcinoma (LCOC-5)\nLow-Grade Serous Carcinoma (LCOC-6)\nOvarian Serous Borderline Epithelial Tumors (Low Malignant Potential) (LCOC-8)\nMalignant Sex Cord-Stromal Tumors (LCOC-11)\nMalignant Germ Cell Tumors (LCOC-12)\nSystemic Therapy Regimens - Malignant Germ Cell/Sex Cord-Stromal Tumors (LCOC-A)\nSurveillance - Malignant Germ Cell/Sex Cord-Stromal Tumors (LCOC-B)\nPrinciples of Surgery (OV-A)\nPrinciples of Pathology (OV-B)\nPrinciples of Systemic Therapy (OV-C)\nManagement of Drug Reactions (OV-D)\nWHO Histologic Classification (OV-E)\nStaging (ST-1)\nAbbreviations (ABBR-1)\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "Ovarian Cancer", "page_from": 3, "page_to": 3, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "0f0e7f2bcdc990e799572d04f917832d7cceb649f2e726cfdee21530cc40e0c0"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000009", "text": "NCCN Guidelines Version 3.2025\nOvarian Cancer\nVersion 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nUPDATES\nUpdates in Version 3.2025 of the NCCN Guidelines for Ovarian Cancer from Version 2.2025 include:\nContinued\nOV-5\n• No Bevacizumab used during primary therapy\n\u0017BRCA1/2 wild-type or unknown, maintenance therapy regimen modified: Niraparib (HR deficient).\nUpdates in Version 2.2025 of the NCCN Guidelines for Ovarian Cancer from Version 1.2025 include:\nOV-4\n• Stage II, III, IV\n\u0017Imaging bullet and footnote a moved from OV-5.\n\u0017Response or Stable Disease pathways added.\nOV-5\n• Response columns removed.\n• No Bevacizumab used during primary therapy\n\u0017BRCA1/2 wild-type or unknown, maintenance therapy regimen added: Olaparib (HR deficient) (category 2B).\n• Bevacizumab used as part of primary therapy\n\u0017BRCA1/2 wild-type or unknown, HR deficient, maintenance therapy regimen added: Olaparib (category 2B).\nLCOC-7\n• Recurrence therapy", "section": "Ovarian Cancer", "page_from": 4, "page_to": 4, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "3e44825c5df5c278c5e1dc163b9efa828e16ae8aa4c1012e2d9ab52ee5c9d05c"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000010", "text": "• Bevacizumab used as part of primary therapy\n\u0017BRCA1/2 wild-type or unknown, HR deficient, maintenance therapy regimen added: Olaparib (category 2B).\nLCOC-7\n• Recurrence therapy\n\u0017Specific regimens removed from this page; all listed in Systemic Therapy sections (OV-C 8 and OV-C 9).\nOV-C (8 of 12)\n• Useful in Certain Circumstances\n\u0017For low-grade serous carcinoma, regimen added: Avutometinib/defactinib (for KRAS-mutated tumors).\nOV-C (9 of 12)\n• Useful in Certain Circumstances\n\u0017For low-grade serous carcinoma, regimen added: Avutometinib/defactinib (for KRAS-mutated tumors).\nOV-C (11 of 12)\n• Reference added: Banerjee S, Nieuwenhuysen EV, Santin A, et al. Avutometinib plus defactinib in recurrent low-grade serous ovarian cancer: A\nsubgroup analysis of ENGOTOV60/ GOG-3052/RAMP 201 Part A. Gyn Oncol 2024;190:S55-S56.\nUpdates in Version 1.2025 of the NCCN Guidelines for Ovarian Cancer from Version 3.2024 include:\nGlobal\n• References have been updated throughout the Guidelines.\n• Imaging footnote revised throughout OV and LCOC algorithms: CT is performed with oral and iodinated IV contrast (unless contraindicated due to", "section": "Ovarian Cancer", "page_from": 4, "page_to": 4, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "d5d140ca1b2c75c58f5f9ed79e5d65905340ab2261234bfa04a8c3e16715393b"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000011", "text": "• Imaging footnote revised throughout OV and LCOC algorithms: CT is performed with oral and iodinated IV contrast (unless contraindicated due to\nanaphylaxis or significant renal dysfunction) and with or without rectal contrast as needed. MRI is performed with gadolinium-based contrast agents\n(unless contraindicated due to anaphylaxis) and is preferred in select patients with renal dysfunction over CT. Chest CT can be done with or without\niodinated IV contrast.\nOV-1\n• Workup\n\u0017Bullet 2 modified: Pelvis ultrasound, and/or abdomen/pelvis CT/MRI as clinically indicated.\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "Ovarian Cancer", "page_from": 4, "page_to": 4, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "f354077ae50c1fbc7d020ed8f6a8b5db268356fe0dbad635e44a37866a9c118a"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000012", "text": "NCCN Guidelines Version 3.2025\nOvarian Cancer\nVersion 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nUPDATES\nUpdates in Version 1.2025 of the NCCN Guidelines for Ovarian Cancer from Version 3.2024 include:\nContinued\n\u0017Bullet 3 modified: Chest CT or chest x-ray as clinically indicated.\n• Footnote c modified: Chest CT preferred If there is concern for metastatic or disseminated disease.\n• Footnote e added: Reconsider REI as clinically indicated once pathologic diagnosis is available.\n• Footnote h, last sentence added: For PARPi therapy in advanced stage disease, include measure of homologous recombination (HR) (OV-B). (Also for\nOV-2, OV-3, and OV-5).\nOV-2\n• Response pathway modified: Interval debulking surgery (IDS) with completion hysterectomy/BSO and cytoreduction. Consider hyperthermic\nintraperitoneal chemotherapy (HIPEC).\n• Stable disease pathway modified: IDS with completion hysterectomy/BSO and cytoreduction. Consider HIPEC.", "section": "Ovarian Cancer", "page_from": 5, "page_to": 5, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "eca1979992df5b9d4b0a856f1daa6a7aa403ae0438e69fdc4fd2d25f1f304433"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000013", "text": "intraperitoneal chemotherapy (HIPEC).\n• Stable disease pathway modified: IDS with completion hysterectomy/BSO and cytoreduction. Consider HIPEC.\n• Pathway added: LCOC with link to LCOC-1.\n• Footnote r added: Neoadjuvant therapy does not apply to low malignant potential (LMP) or other noninvasive cancers (see LCOC-1). (Also for OV-3)\n• Footnote removed: Hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin (100 mg/m2) can be considered at the time of IDS for stage III\ndisease.\nOV-3\n• Diagnosis by previous surgery modified: Patient referred with newly diagnosed ovarian cancer, including less common ovarian cancers (LCOCs), after\nrecent surgical procedure.\n• Bullet 5 modified: Imaging as clinically indicated (eg, C/A/P CT, chest CT, A/P MRI, PET/MRI, PET/CT, and/or pelvis ultrasound).\n• Bullet 8 added: REI as clinically indicated.\nOV-5\n• Stage II, III, IV, post primary treatment, bullet 1, sub-bullet modified: eg, C/A/P CT, chest CT, A/P MRI, PET/MRI, PET/CT and/or pelvis ultrasound)\n(skull base to mid-thigh).\nOV-6\n• Heading modified: Monitoring/Follow-up for Patients Not Receiving Treatment", "section": "Ovarian Cancer", "page_from": 5, "page_to": 5, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "7e739060c7990d8fc60b32338ba464e49dee9dd1bd24837f102508aade7c63f5"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000014", "text": "(skull base to mid-thigh).\nOV-6\n• Heading modified: Monitoring/Follow-up for Patients Not Receiving Treatment\n• Bullet 3 modified: Imaging as clinically indicated (eg, C/A/P CT, chest CT, A/P MRI, PET/MRI, PET/CT and/or pelvis ultrasound)(skull base to mid-thigh)\nas clinically indicated.\nOV-7\n• Footnote jj modified: Patients who do not respond and progress on two consecutive therapy regimens without evidence of clinical benefits have\ndiminished likelihood of benefitting from additional therapy (Griffiths RW, et al. Int J Gynecol Cancer 2011;21:58-65). Decisions to offer clinical trials,\nsupportive care only, or additional therapy should be made on an highly individual basis.\nLCOC-2\n• Footnote i, last sentence added: For PARPi therapy in advanced stage disease, include measure of HR (OV-B). (Also for LCOC-3)\nLCOC-4\n• Mucinous neoplasms of the ovary\n\u0017Stage IA, IB, and IC carcinoma split into separate pathways.\n\u0017Adjuvant therapy for each stage updated based on expansile or infiltrative pattern.\n• Footnote d added: Principles of Pathology (OV-B).\nLCOC-7", "section": "Ovarian Cancer", "page_from": 5, "page_to": 5, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "ba104779286d7c3e52cbd8648c3a286067d425ffefe229caa2b6f0fe882e250c"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000015", "text": "\u0017Adjuvant therapy for each stage updated based on expansile or infiltrative pattern.\n• Footnote d added: Principles of Pathology (OV-B).\nLCOC-7\n• Bullet 4 modified: Imaging as clinically indicated (eg, C/A/P CT, chest CT, A/P MRI, PET/CT, PET/MRI)(skull base to mid-thigh) as clinically indicated.\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "Ovarian Cancer", "page_from": 5, "page_to": 5, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "78bd19d2a8f82fd90eac4b7bdee4ae5fae26cb9df6d99a3d38392b18a30547b7"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000016", "text": "NCCN Guidelines Version 3.2025\nOvarian Cancer\nVersion 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nUPDATES\nUpdates in Version 1.2025 of the NCCN Guidelines for Ovarian Cancer from Version 3.2024 include:\nContinued\nLCOC-9\n• Pathologic diagnosis pathway modified: Imaging C/A/P CT with contrast if not previously done.\n\u0017Bullet added: eg, C/A/P CT, chest CT, A/P MRI, PET/CT, or PET/MRI.\nLCOC-10\n• Bullet 5 modified: Imaging as clinically indicated: eg, C/A/P CT, chest CT, A/P MRI, PET/CT, PET/MRI (skull base to mid-thigh). (also for LCOC-13)\nLCOC-12\n• Incompletely staged, modified: Imaging if not previously done (eg, C/A/P CT, chest CT, A/P MRI, PET/CT, PET/MRI) with contrast (if not previously\ndone).\nLCOC-A\n• Footnote removed: An FDA-approved biosimilar is an appropriate substitute for bevacizumab.\nLCOC-B\n• Surveillance for Malignant Germ Cell Tumors extensively revised.\n• Footnote a added: Only for those patients who have a residual ovary.\nOV-A (3 of 4)", "section": "Ovarian Cancer", "page_from": 6, "page_to": 6, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "ef887c75996df2ebcad0e9a2a830dcc48e1ecfd4e8e6de8f557016d279f3b518"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000017", "text": "LCOC-B\n• Surveillance for Malignant Germ Cell Tumors extensively revised.\n• Footnote a added: Only for those patients who have a residual ovary.\nOV-A (3 of 4)\n• Interval Debulking Surgery After Neoadjuvant Chemotherapy of Invasive Epithelial Ovarian Cancer\n\u0017Bullet 2 modified: HIPEC with cisplatin (100 mg/m2) can be considered at the time of IDS for stage III disease. HIPEC can also be considered for\nsuitable stage IV patients (category 2B) who have had a favorable response to neoadjuvant therapy both intraperitoneally and extraperitoneally,\nor in whom stage IV disease sites have completely resolved (eg, resolution of malignant pleural effusion) or are now deemed resectable. Sodium\nthiosulfate may be administered at the start of perfusion, followed by a continuous infusion, to allow for renal protection during HIPEC.\n\u0017Bullet 5 modified: While systemic lymphadenectomy of clinical-negative nodes is not recommended, suspicious and/or enlarged nodes should be\nresected, if possible. Removal of lymph nodes noted to have potential metastasis at the time of initial diagnosis should be considered, even if not\ncurrently suspicious or enlarged.\nOV-A (4 of 4)", "section": "Ovarian Cancer", "page_from": 6, "page_to": 6, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "c65235b76c63d64f6b0ddb00db83291f59231795e39ef6d88b0dd73a4242adb9"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000018", "text": "resected, if possible. Removal of lymph nodes noted to have potential metastasis at the time of initial diagnosis should be considered, even if not\ncurrently suspicious or enlarged.\nOV-A (4 of 4)\n• Special Circumstances, bullet 1, sub-bullet, second sentence added: Consider endometrial sampling to exclude synchronous primary or hyperplasia.\nOV-B (2 of 3)\n• Less Common Ovarian Cancers (LCOC)\n\u0017Bullet 3, last sentence added: Features favoring primary ovarian carcinoma versus metastasis are: unilateral, \"expansile\" pattern of invasion, complex\npapillary pattern, size >10 cm, smooth external surface, microscopic cystic glands, necrotic luminal debris, mural nodules, and accompanying\nteratoma, adenofibroma, endometriosis, or Brenner tumor.\nOV-B (2 of 3)(continued)\n\u0017Bullet 4 added: Most early stage invasive mucinous ovarian cancers have an expansile pattern of growth characterized by complex glandular,\npapillary and/or cribriform architecture with a labyrinthine or anastomosing pattern and little or no intervening stroma. About 20% have an infiltrative", "section": "Ovarian Cancer", "page_from": 6, "page_to": 6, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "9dffee8ffe0aa7139b58fd705ecb8350749bd469c6c8557e99b78b180f88ced8"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000019", "text": "papillary and/or cribriform architecture with a labyrinthine or anastomosing pattern and little or no intervening stroma. About 20% have an infiltrative\npattern of destructive invasion of haphazardly arranged and angulated tumor cell nests into a desmoplastic stroma and measuring at least 5 mm in\nlinear extent - and this has been associated with an increased risk of relapse and mortality.\n\u0017Bullet 5 modified: Metastatic colorectal adenocarcinomas also usually are positive for CK20 and CEA.\n\u0017Bullet 6, second sentence modified: Endometrioid adenocarcinomas are usually positive for cytokeratin 7 (CK7), PAX8, CA-125, and estrogen\nreceptors.\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "Ovarian Cancer", "page_from": 6, "page_to": 6, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "457261bdb555a604b294656a5f8d081599bfa41d706a43341b4c96b4d04524bb"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000020", "text": "NCCN Guidelines Version 3.2025\nOvarian Cancer\nVersion 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nUPDATES\nUpdates in Version 1.2025 of the NCCN Guidelines for Ovarian Cancer from Version 3.2024 include:\nOV-C (1 of 12)\n• General\n\u0017Bullet 3, sub-bullet 2 modified: Patients of childbearing potential who desire fertility-sparing procedures should be referred to an appropriate\nfertility specialist (see Fertility, Reproductive Endocrine, and Sexual Health Considerations for Individuals with Ovaries in the NCCN Guidelines for\nAdolescent and Young Adult (AYA) Oncology).\n\u0017Bullet 8 added: An FDA-approved biosimilar is an appropriate substitute for any recommended systemic biologic therapy in the NCCN Guidelines.\nOV-C (2 of 12)\n• Language updated: \"Surgery\" has replaced \"IDS\" throughout this page.\n• Bullet 2 modified: Any of the primary IV regimens for stage II–IV high-grade serous carcinoma and respective LCOCs can be used as neoadjuvant", "section": "Ovarian Cancer", "page_from": 7, "page_to": 7, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "75a95f2b42faa9f6f8679a9016f7aa05ab4bcf8d13768e422540aca9f79053c6"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000021", "text": "• Bullet 2 modified: Any of the primary IV regimens for stage II–IV high-grade serous carcinoma and respective LCOCs can be used as neoadjuvant\ntherapy before surgery. Neoadjuvant therapy does not apply to LMP and other noninvasive cancers. See OV-C (6 of 12) and LCOC-A.\n• Bullet 4 modified: After neoadjuvant therapy and surgery any of the adjuvant therapy options for high-grade serious carcinoma (IV or IP/IV) and\nrespective LCOCs can be considered. Neoadjuvant therapy does not apply to LMP and other noninvasive cancers. See OV-C (6 of 12) and LCOC-A.\nOV-C (3 of 12)\n• Principles of Maintenance PARP Inhibitor (PARPi) Therapy, bullet 3, sub-bullet 7 added: Current clinical HRD tests are proxy measures of HRD and\nlack accuracy in fully predicting functional HRD. HRD testing is recommended for those patients without germline BRCA1/2 mutations as HRD test\nstatus may provide information on the magnitude of benefit of PARP inhibitor maintenance therapy in these patients. The Panel considers the use of\nPARPi in patients who have HRP tumors, at present, to be of minimal benefit.\nOV-C (4 of 12)", "section": "Ovarian Cancer", "page_from": 7, "page_to": 7, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "cf247d7a64eec0563573b2aeb66aa12f9e8c2cebc7baab300ac06e8462dcbd51"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000022", "text": "PARPi in patients who have HRP tumors, at present, to be of minimal benefit.\nOV-C (4 of 12)\n• Bullet 9 moved from OV-C (9A of 12): Patients who do not respond and progress on two consecutive regimens without evidence of clinical benefits\nhave diminished likelihood of benefitting from additional therapy (Griffiths RW, et al. Int J Gynecol Cancer 2011;21:58-65). Decisions to offer clinical\ntrials, supportive care, or additional therapy should be made on an individual basis.\nOV-C (5 of 12)\n• Mucinous carcinoma row header modified: Mucinous carcinoma (stage IA, IB, and IC, grades 1–3).\nOV-C (6 of 12)\n• Footnote h, sentence removed: See the NCCN Guidelines for Older Adult Oncology.\n• Footnote removed: An FDA-approved biosimilar is an appropriate substitute for bevacizumab. (also for OV-C [7 of 12], [8 of 12] and [9A of 12]).\nOV-C (8 of 12)\n• Useful in Certain Circumstances, Targeted Therapy\n\u0017Regimen added: Fam-trastuzumab deruxtecan-nxki (for HER2-positive tumors [IHC 3+ or 2+])(category 2B).\n\u0017Regimen added: Mirvetuximab soravtansine-gynx (for FRα-expressing tumors [≥75% positive tumor cells]).", "section": "Ovarian Cancer", "page_from": 7, "page_to": 7, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "3b6b1682c2aee3f8e79126b870b84306ee43504baf06858770a79c0d0eabbd4b"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000023", "text": "\u0017Regimen added: Mirvetuximab soravtansine-gynx (for FRα-expressing tumors [≥75% positive tumor cells]).\n\u0017Regimen modified: Mirvetuximab soravtansine-gynx/bevacizumab (for FRα-expressing tumors [≥50% positive tumor cells])(category 2B).\nOV-C (8 of 12)(continued)\n• Footnote y added: For patients treated with two prior lines of platinum-based therapy.\n• Footnote removed: Patients who progress on two consecutive regimens without evidence of clinical benefits have diminished likelihood of benefitting\nfrom additional therapy (Griffiths RW, et al. Int J Gynecol Cancer 2011;21:58-65). Decisions to offer clinical trials, supportive care, or additional therapy\nshould be made on an individual basis. (Also for OV-C [9A of 12])\nOV-C (9 of 12)\n• Useful in Certain Circumstances, Targeted Therapy\n\u0017Regimen modified: Mirvetuximab soravtansine-gynx/bevacizumab (for FRα-expressing tumors [≥25% positive tumor cells]).\n\u0017Regimen added: For mucinous carcinoma: FOLFIRI ± bevacizumab (category 2B).\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.", "section": "Ovarian Cancer", "page_from": 7, "page_to": 7, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "cb458e9909d98db43a3b230ba61c88b669311a440d97f72e951f08aff50ea2bf"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000024", "text": "PLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "Ovarian Cancer", "page_from": 7, "page_to": 7, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "5e18f3d122f5f5c0bf62f64f178763607a64102384a3a5517f96df1222be28d4"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000025", "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nEpithelial Ovarian Cancer/Fallopian Tube Cancer/\nPrimary Peritoneal Cancer\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nOV-1\nCLINICAL\nPRESENTATION\nWORKUP\nPRIMARY TREATMENTi,j,k\nSuspicious/\npalpable pelvic\nmass on abdomen/\npelvis exam and/or\nascites, abdominal\ndistention\nand/or\nSymptoms\nwithout source of\nmalignancy (ie,\nbloating, pelvis/\nabdomen pain,\ndifficulty eating or\nfeeling full quickly,\nurinary symptoms\n[urgency or\nfrequency])\nPathologic\nStaging\n(OV-4)\nPatients with\novarian cancer,\nfallopian\ntube cancer,\nor primary\nperitoneal\ncancer should\nhave genetic\nrisk evaluation\nand germline\nand somatic\ntesting (if not\npreviously\ndone)f,g,h,k\n• Abdominal/pelvic exam\n• Pelvis ultrasound, abdomen/\npelvis CT/MRI as clinically\nindicateda,b\n• Chest CT as clinically\nindicateda,c\n• Complete blood count (CBC),\nchemistry profile with liver\nfunction test (LFT)", "section": "Primary Peritoneal Cancer", "page_from": 8, "page_to": 8, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "1f798a9a42f40c9827f42ec407f3e81f7bbe0de76b4dbb8a581dd481e7577dd1"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000026", "text": "• Pelvis ultrasound, abdomen/\npelvis CT/MRI as clinically\nindicateda,b\n• Chest CT as clinically\nindicateda,c\n• Complete blood count (CBC),\nchemistry profile with liver\nfunction test (LFT)\n• CA-125 or other tumor markers\nas clinically indicatedd\n• Evaluate performance status\nand nutritional status\n• Gastrointestinal (GI) evaluation\nas clinically indicated\n• Reproductive endocrinology\nand infertility (REI) evaluation as\nclinically indicatede\n• Obtain family historyf,g,h\n• Refer to gynecologic oncologist\nfor clinically suspicious lesionsi\na CT is performed with oral and iodinated IV contrast (unless contraindicated due to anaphylaxis\nor significant renal dysfunction) with or without rectal contrast. MRI is performed with gadolinium-\nbased contrast agents (unless contraindicated due to anaphylaxis) and is preferred in select\npatients with renal dysfunction over CT. Chest CT can be done with or without iodinated IV\ncontrast.\nb PET/CT, MRI, or PET/MRI may be indicated for indeterminate lesions if results will alter\nmanagement.\nc If there is concern for metastatic or disseminated disease.\nd Other tumor markers may include inhibin, beta-human chorionic gonadotropin (β-hCG), alpha-", "section": "Primary Peritoneal Cancer", "page_from": 8, "page_to": 8, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "dd9345e07ed242730813696adc986a99c8ddbadef0c0932366edf6ef8cc18431"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000027", "text": "management.\nc If there is concern for metastatic or disseminated disease.\nd Other tumor markers may include inhibin, beta-human chorionic gonadotropin (β-hCG), alpha-\nfetoprotein, lactate dehydrogenase (LDH), carcinoembryonic antigen (CEA), CA 19-9, and HE4.\nSee Discussion for usefulness of diagnostic tests.\ne Reconsider REI as clinically indicated once pathologic diagnosis is available.\nf See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic,\nand Prostate and NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal,\nEndometrial, and Gastric.\ng Germline and somatic BRCA1/2 status informs maintenance therapy.\nh In the absence of a BRCA1/2 mutation, homologous recombination deficiency (HRD) status may\nprovide information on the magnitude of benefit of PARP inhibitor (PARPi) therapy. For PARPi\ntherapy in advanced stage disease, include measure of homologous recombination (HR) (OV-B).\ni Evaluation by a gynecologic oncologist is recommended for:\n•\tAll patients with suspected ovarian malignancies; published data demonstrate that primary\nassessment and debulking by a gynecologic oncologist results in a survival advantage.", "section": "Primary Peritoneal Cancer", "page_from": 8, "page_to": 8, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "5aab1ca12c8c791c20f9ed76820871e46b036f01c4e875a53c645370150a8a07"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000028", "text": "•\tAll patients with suspected ovarian malignancies; published data demonstrate that primary\nassessment and debulking by a gynecologic oncologist results in a survival advantage.\n•\tPatients being evaluated for neoadjuvant therapy prior to being considered a poor surgical\ncandidate.\n•\tManagement of occult STICs.\n•\tConsideration of laparoscopic evaluation to determine feasibility of debulking surgery in select\npatients.\n•\tEndometrial biopsy as clinically indicated.\nj Principles of Surgery (OV-A).\nk Principles of Pathology (OV-B).\nl May be an option for select patients with stage IC based on histology.\nm Uterine preservation for potential future assisted reproductive approaches.\nn See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D).\no Carcinosarcoma, clear cell, mucinous, low-grade serous, grade 1 endometrioid, borderline\nepithelial, malignant sex cord-stromal tumors, and germ cell tumors.\nIA (fertility\ndesired)\nIB (fertility\ndesired)\nIA–IV, surgical\ncandidate, optimal\ncytoreduction\nlikely (fertility not\ndesired)\nPoor surgical candidate\nor\nLow likelihood of optimal\ncytoreductionj\nUnilateral salpingo-oophorectomy\n(USO) + comprehensive surgical", "section": "Primary Peritoneal Cancer", "page_from": 8, "page_to": 8, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "1ee3579fc71e51a2ec1e75ebefea0b9f48e8991c3ff4e41daaf3d7a322b2d375"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000029", "text": "candidate, optimal\ncytoreduction\nlikely (fertility not\ndesired)\nPoor surgical candidate\nor\nLow likelihood of optimal\ncytoreductionj\nUnilateral salpingo-oophorectomy\n(USO) + comprehensive surgical\nstagingj,k,l,m\nHysterectomy/BSO +\ncomprehensive stagingj,k\nand debulking as needed\nNeoadjuvant Therapy (OV-2)n\nCLINICAL\nSTAGEi\nDiagnosis by previous surgery or tissue biopsy (cytopathology)\nWorkup, Findings, and Primary Treatment (OV-3)\nBilateral salpingo-oophorectomy\n(BSO) + comprehensive surgical\nstagingj,k,l,m\nFor less\ncommon\novarian\ncancers\n(LCOC),o\nsee\nLCOC-1\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "Primary Peritoneal Cancer", "page_from": 8, "page_to": 8, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "7288599f59e9a35b15c0125cdc3b50132a86890cf793bb570f1d25a6d8c04e44"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000030", "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nEpithelial Ovarian Cancer/Fallopian Tube Cancer/\nPrimary Peritoneal Cancer\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nIDS with completion\nhysterectomy/BSOj,k and\ncytoreduction. Consider\nHIPEC.j\nor\nContinue current therapy (for\na total of at least 6 cycles)n\nor\nTherapy for Persistent\nDisease or Recurrence (OV-7)\nOV-2\nf See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic,\nand Prostate and NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal,\nEndometrial, and Gastric.\ng Germline and somatic BRCA1/2 status informs maintenance therapy.\nh In the absence of a BRCA1/2 mutation, HRD status may provide information on the\nmagnitude of benefit of PARPi therapy. For PARPi therapy in advanced stage disease, include\nmeasure of HR (OV-B).\ni Evaluation by a gynecologic oncologist is recommended for:", "section": "Primary Peritoneal Cancer", "page_from": 9, "page_to": 9, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "a229d306409334b5369ffca290ceaca5e28817b92debeab660df36f0a61b1874"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000031", "text": "magnitude of benefit of PARPi therapy. For PARPi therapy in advanced stage disease, include\nmeasure of HR (OV-B).\ni Evaluation by a gynecologic oncologist is recommended for:\n•\tAll patients with suspected ovarian malignancies; published data demonstrate that primary\nassessment and debulking by a gynecologic oncologist results in a survival advantage.\n•\tPatients being evaluated for neoadjuvant therapy prior to being considered a poor surgical\ncandidate.\n•\tManagement of occult STICs.\n•\tConsideration of laparoscopic evaluation to determine feasibility of debulking surgery in\nselect patients.\n•\tEndometrial biopsy as clinically indicated.\nj Principles of Surgery (OV-A).\nk Principles of Pathology (OV-B).\nn See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D).\np If biopsy is not feasible, cytopathology from ascites or pleural effusion combined with CA-\n125:CEA ratio of >25 can be used.\nq Completion surgery after 3–4 cycles is preferred; however, surgery may be performed after\n4–6 cycles based on the clinical judgment of the gynecologic oncologist.\nr Neoadjuvant therapy does not apply to low malignant potential (LMP) or other noninvasive\ncancers (see LCOC-1).", "section": "Primary Peritoneal Cancer", "page_from": 9, "page_to": 9, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "4166ee47c8c9c5dd7f065241997c77f233f7da4f0daebf9f573beeee534dca98"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000032", "text": "4–6 cycles based on the clinical judgment of the gynecologic oncologist.\nr Neoadjuvant therapy does not apply to low malignant potential (LMP) or other noninvasive\ncancers (see LCOC-1).\nNeoadjuvant\ntherapyi,n,q,r\n(category 1)\nand\nGenetic risk\nevaluation and\ngermline and\nsomatic testing\n(if not previously\ndone)f,g,h,k\nEvaluation by\ngynecologic\noncologisti,j\nand\nHistologic\nconfirmationk,p\n(biopsy preferred)\nand/or\nLaparoscopic\nevaluation to\ndetermine feasibility\nof resection\nResponse\nInterval debulking surgery\n(IDS) with completion\nhysterectomy/BSOj,k and\ncytoreduction. Consider\nhyperthermic intraperitoneal\nchemotherapy (HIPEC).j\nProgressive disease\nIDS with completion\nhysterectomy/BSOj,k and\ncytoreduction. Consider\nHIPEC.j\nor\nTherapy for Persistent\nDisease or Recurrence\n(OV-7)\nTherapy for Persistent Disease or\nRecurrence (OV-7)\nMaintenance\nTherapy\n(OV-5)\nAdjuvant\ntherapyn\nPOOR SURGICAL CANDIDATE OR LOW LIKELIHOOD OF OPTIMAL CYTOREDUCTION\nNEOADJUVANT THERAPY\nPRIMARY TREATMENT\nConfirmed\npoor surgical\ncandidate or\nlow likelihood\nof optimal\ncytoreduction\nStable\ndisease\nLCOC-1\nLCOC", "section": "Primary Peritoneal Cancer", "page_from": 9, "page_to": 9, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "2aefa858b0899bbe312160686d06474cfd9198ae93d9676afc06ae60f6b00d7a"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000033", "text": "NEOADJUVANT THERAPY\nPRIMARY TREATMENT\nConfirmed\npoor surgical\ncandidate or\nlow likelihood\nof optimal\ncytoreduction\nStable\ndisease\nLCOC-1\nLCOC\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "Primary Peritoneal Cancer", "page_from": 9, "page_to": 9, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "b09637d4781a70c651c83a53856ee1953929ab54f2bfda7702909ad8851f91b3"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000034", "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nEpithelial Ovarian Cancer/Fallopian Tube Cancer/\nPrimary Peritoneal Cancer\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nOV-3\nDIAGNOSIS BY PREVIOUS SURGERY\nFINDINGS\nPatient\nreferred\nwith newly\ndiagnosed\novarian\ncancer,\nincluding\nless common\novarian\ncancers\n(LCOCs),\nafter recent\nsurgical\nprocedure\nConsider surgical stagingj,k (if not\npreviously done) if considering\nobservation or to inform systemic\ntherapy decisionss\nTumor\ncytoreductive\nsurgeryj,k\nNeoadjuvant Therapy (OV-2)\nSuspect\nresectable\nresidual disease\nSuspect\nunresectable\nresidual diseaser\nAdjuvant\nTherapy\n(OV-4)\na CT is performed with oral and iodinated IV contrast (unless contraindicated due to\nanaphylaxis or significant renal dysfunction) with or without rectal contrast. MRI is\nperformed with gadolinium-based contrast agents (unless contraindicated due to", "section": "Primary Peritoneal Cancer", "page_from": 10, "page_to": 10, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "936887ebd81d20356fadbd0ad9a7dbee71099aff671b5dfd3f229d51c9a15d5a"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000035", "text": "anaphylaxis or significant renal dysfunction) with or without rectal contrast. MRI is\nperformed with gadolinium-based contrast agents (unless contraindicated due to\nanaphylaxis) and is preferred in select patients with renal dysfunction over CT. Chest CT\ncan be done with or without iodinated IV contrast.\nd Other tumor markers may include inhibin, β-hCG, alpha-fetoprotein, LDH, CEA, CA 19-9,\nand HE4. See Discussion for usefulness of diagnostic tests.\nf See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian,\nPancreatic, and Prostate and NCCN Guidelines for Genetic/Familial High-Risk Assessment:\nColorectal, Endometrial, and Gastric.\ng Germline and somatic BRCA1/2 status informs maintenance therapy.\nh In the absence of a BRCA1/2 mutation, HRD status may provide information on the\nmagnitude of benefit of PARPi therapy. For PARPi therapy in advanced stage disease,\ninclude measure of HR (OV-B).\ni Evaluation by a gynecologic oncologist is recommended for:\n•\tAll patients with suspected ovarian malignancies; published data demonstrate that\nprimary assessment and debulking by a gynecologic oncologist results in a survival\nadvantage.", "section": "Primary Peritoneal Cancer", "page_from": 10, "page_to": 10, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "745557df1061aa436632fc10b83f0345cb8bbda8d4e28fd332305266d7f26ad0"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000036", "text": "•\tAll patients with suspected ovarian malignancies; published data demonstrate that\nprimary assessment and debulking by a gynecologic oncologist results in a survival\nadvantage.\n•\tPatients being evaluated for neoadjuvant therapy prior to being considered a poor\nsurgical candidate.\n•\tManagement of occult STICs.\n•\tConsideration of laparoscopic evaluation to determine feasibility of debulking surgery in\nselect patients.\n•\tEndometrial biopsy as clinically indicated.\nj Principles of Surgery (OV-A).\nk Principles of Pathology (OV-B).\nr Neoadjuvant therapy does not apply to LMP and other noninvasive cancers (see LCOC-1).\ns Although comprehensive surgical staging has not been shown to improve survival in\npatients with no evidence of residual disease, it can be important for determining the\nmost appropriate postoperative management options, including selection of adjuvant and\nmaintenance therapy.\n• Evaluation by gynecologic\noncologisti\n• Obtain family historyf\n• Genetic risk evaluation and\ngermline and somatic testingf,g,h\n(if not previously done)\n• Review prior imaging studies,\noperative notes, and pathologyk\n• Imaging as clinically indicateda\n(eg, C/A/P CT, chest CT, A/P MRI,", "section": "Primary Peritoneal Cancer", "page_from": 10, "page_to": 10, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "60731661ab66f15c6582337483330da3013a914753607b1ed4a2f6ca232ac318"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000037", "text": "germline and somatic testingf,g,h\n(if not previously done)\n• Review prior imaging studies,\noperative notes, and pathologyk\n• Imaging as clinically indicateda\n(eg, C/A/P CT, chest CT, A/P MRI,\nPET/MRI, PET/CT, and/or pelvis\nultrasound)\n• CBC, chemistry profile with LFTs\n• CA-125 or other tumor markers\nas clinically indicatedd\n• REI as clinically indicated\nPRIMARY TREATMENT\nEvidence of residual\ndisease on workup\nNo evidence of residual\ndisease on workup\n(suspect stage I)\nNo evidence of residual\ndisease on workup\n(suspect stage II–IV)\nConsider surgical stagingj,k if\nnot previously done, to inform\nsystemic therapy decisionss\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "Primary Peritoneal Cancer", "page_from": 10, "page_to": 10, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "42c1568404a32f5041e3d517cca87e03183fe1a7c278713838f2211527014638"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000038", "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nEpithelial Ovarian Cancer/Fallopian Tube Cancer/\nPrimary Peritoneal Cancer\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nOV-4\nPATHOLOGIC STAGINGt,u\nStage IA or IB\nStage lC\n(High-grade serous or\ngrade 2/3 endometrioid)\nStage II\nStage III\nStage IV\nIV platinum-based therapyn,v\n(see primary regimens for\nstage I disease [OV-C, 5 of 12])\nObserve\nor\nIntravenous (IV) platinum-based\ntherapyn,v (see primary regimens for\nstage I disease [OV-C, 5 of 12])\nMonitoring/\nFollow-up\n(OV-6)\nMaintenance\nTherapy (OV-5)\na CT is performed with oral and iodinated IV contrast (unless contraindicated due\nto anaphylaxis or significant renal dysfunction) with or without rectal contrast. MRI\nis performed with gadolinium-based contrast agents (unless contraindicated due\nto anaphylaxis) and is preferred in select patients with renal dysfunction over CT.", "section": "Primary Peritoneal Cancer", "page_from": 11, "page_to": 11, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "5f0b307e22a475120ab3fe7243ca72d0910318156b321769a51887328ee991b6"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000039", "text": "is performed with gadolinium-based contrast agents (unless contraindicated due\nto anaphylaxis) and is preferred in select patients with renal dysfunction over CT.\nChest CT can be done with or without iodinated IV contrast.\nn See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions\n(OV-D).\no Carcinosarcoma, clear cell, mucinous, low-grade serous, grade 1 endometrioid,\nborderline epithelial, malignant sex cord-stromal tumors, and germ cell tumors.\nt Pathologists recommend categorizing serous ovarian cancer as either low-grade\nor high-grade. Grade 2 serous is considered high-grade.\nu Consider expert pathologic review to confirm histologic diagnosis. See WHO\nHistologic Classification (OV-E).\nv Patients receiving primary chemotherapy will be monitored as follows:\n1. Every 1–3 cycles: Physical exam and consider pelvic exam\n2. As indicated: Interim CBC and chemistry profiles\n3. \u0007CA-125 levels or other tumor markers as clinically indicated prior to each cycle\nof chemotherapy\n4. \u0007C/A/P CT or MRI with contrast, PET/CT (skull base to mid-thigh), or PET as\nindicated.\nx No definitive evidence of disease.\nGrade 2 endometrioid\nGrade 3 endometrioid/\nhigh-grade serous\ncarcinomat", "section": "Primary Peritoneal Cancer", "page_from": 11, "page_to": 11, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "3f40385e46d2fab6ebc85525bb868855432117eebb19522d71688e9bec9bccd7"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000040", "text": "4. \u0007C/A/P CT or MRI with contrast, PET/CT (skull base to mid-thigh), or PET as\nindicated.\nx No definitive evidence of disease.\nGrade 2 endometrioid\nGrade 3 endometrioid/\nhigh-grade serous\ncarcinomat\nPlatinum-based\nchemotherapy\n(see primary\nregimens for stage\nII–IV disease [OV-C,\n6 of 12])n,v\nPRIMARY CHEMOTHERAPY/PRIMARY ADJUVANT THERAPYv\nProvide symptom\nmanagement and\nbest supportive care.\nRefer for palliative\ncare assessment, if\nappropriate.\n• See NCCN Guidelines\nfor Palliative Care\n• See NCCN Guidelines\nfor Survivorship\n• Provide symptom\nmanagement and\nbest supportive care.\nRefer for palliative\ncare assessment, if\nappropriate.\n\u0017See NCCN Guidelines\nfor Palliative Care\n\u0017See NCCN Guidelines\nfor Survivorship\nLCOC-1\nLess common ovarian cancers (LCOC), any stageo,u\nComplete\nResponse\n(CR)x/Partial\nResponse (PR)\nStable disease\nor progression\nTherapy for Persistent\nDisease or Recurrence\n(OV-7)\nImaginga\nas clinically\nindicated:\neg, C/A/P CT, chest\nCT, A/P MRI, PET/\nMRI, PET/CT (skull\nbase to mid-thigh)\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.", "section": "Primary Peritoneal Cancer", "page_from": 11, "page_to": 11, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "b207b54b7c8dbe4b1067c7138db035d0a7a6c43dc19ff0df472ed933fea404c2"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000041", "text": "PLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "Primary Peritoneal Cancer", "page_from": 11, "page_to": 11, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "5e18f3d122f5f5c0bf62f64f178763607a64102384a3a5517f96df1222be28d4"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000042", "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nEpithelial Ovarian Cancer/Fallopian Tube Cancer/\nPrimary Peritoneal Cancer\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nCRx/PR\nOV-5\nSTAGE II, III, IVw\nPOST PRIMARY TREATMENT\nHR\ndeficient\nHomologous\nrecombination (HR)\nproficient or status\nunknown\nOlaparib (category 1)\nor\nNiraparib (category 1)\nor\nRucaparib\nor\nObserve for select stage II disease with CR\nObserve (if CR)\nor\nNiraparib (HR deficient)\nor\nRucaparib\nor\nOlaparib (HR deficient) (category 2B)\nor\nTherapy for Persistent Disease or Recurrence (OV-7)\nMonitoring/\nFollow-up (OV-6)\nMonitoring/\nFollow-Up (OV-6)\nMAINTENANCE THERAPYh,n,y\nBevacizumab\nused as part\nof primary\ntherapy\nNo\nbevacizumab\nused during\nprimary\ntherapy\nGermline\nor somatic\nBRCA1/2\nmutation\nBRCA1/2\nwild-type or\nunknownh\nGermline\nor somatic\nBRCA1/2\nmutation\nBRCA1/2\nwild-type or\nunknownh\nBevacizumab + olaparib (category 1)\nor", "section": "Primary Peritoneal Cancer", "page_from": 12, "page_to": 12, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "95ae6dadcbfe2a4ad849d0b88c400a6012db7ae8bc89cc687baa61c4bac0ae51"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000043", "text": "primary\ntherapy\nGermline\nor somatic\nBRCA1/2\nmutation\nBRCA1/2\nwild-type or\nunknownh\nGermline\nor somatic\nBRCA1/2\nmutation\nBRCA1/2\nwild-type or\nunknownh\nBevacizumab + olaparib (category 1)\nor\nBevacizumab + niraparib (if unable to tolerate olaparib)\nor\nBevacizumab\nor\nOlaparib (category 2B)\nBevacizumab + olaparib (category 1)\nor\nBevacizumab + niraparib (if unable to tolerate\nolaparib)\nor\nOlaparibz\nor\nNiraparibz\nor\nRucaparibz\nh In the absence of a BRCA1/2 mutation, HRD status may provide information on the\nmagnitude of benefit of PARPi therapy. For PARPi therapy in advanced stage disease,\ninclude measure of HR (OV-B).\nn See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D).\nw Post primary treatment recommendations for stage II–IV high-grade serous or grade 2/3\nendometrioid carcinoma; consider for clear cell carcinoma or carcinosarcoma with a BRCA1/2\nmutation.\nx No definitive evidence of disease.\ny Data are limited for maintenance therapy with a PARPi for patients with stage II disease.\nz After first-line therapy with bevacizumab, data are limited on maintenance therapy with a", "section": "Primary Peritoneal Cancer", "page_from": 12, "page_to": 12, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "f0880c832c51ef23c064a9a0a7379b00a7bcaa257bdfcf310f6641030b4dea15"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000044", "text": "y Data are limited for maintenance therapy with a PARPi for patients with stage II disease.\nz After first-line therapy with bevacizumab, data are limited on maintenance therapy with a\nsingle-agent PARPi (olaparib, niraparib, or rucaparib) for patients with a germline or somatic\nBRCA1/2 mutation. However, based on the magnitude of benefit of PARPi maintenance\ntherapy for other subgroups, single-agent PARPi can be considered.\nBevacizumab\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "Primary Peritoneal Cancer", "page_from": 12, "page_to": 12, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "66e2098bf7ae8a72ec12559e3af66204e1dc74800dd7377734dc45de4986c4af"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000045", "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nEpithelial Ovarian Cancer/Fallopian Tube Cancer/\nPrimary Peritoneal Cancer\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nOV-6\nMONITORING/FOLLOW-UP FOR\nPATIENTS NOT RECEIVING\nTREATMENT\nRECURRENT DISEASEbb\nStage I, II,\nIII, and\nIV after\nprimary\ntreatment\na CT is performed with oral and iodinated IV contrast (unless contraindicated due to\nanaphylaxis or significant renal dysfunction) with or without rectal contrast. MRI is\nperformed with gadolinium-based contrast agents (unless contraindicated due to\nanaphylaxis) and is preferred in select patients with renal dysfunction over CT. Chest\nCT can be done with or without iodinated IV contrast.\nf See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian,\nPancreatic, and Prostate and NCCN Guidelines for Genetic/Familial High-Risk\nAssessment: Colorectal, Endometrial, and Gastric.", "section": "Primary Peritoneal Cancer", "page_from": 13, "page_to": 13, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "57a361e836f5105da496016f0193d5e8c2b4338c5cf58feef79c33156ce14bb2"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000046", "text": "Pancreatic, and Prostate and NCCN Guidelines for Genetic/Familial High-Risk\nAssessment: Colorectal, Endometrial, and Gastric.\nn See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-\nD).\naa There are data regarding the utility of CA-125 for monitoring of ovarian cancer after\ncompletion of primary therapy. See The Society of Gynecologic Oncology (SGO)\nposition statement and Discussion.\n• Imaging studies as\nclinically indicateda,cc:\nC/A/P CT, MRI, PET/CT, or\nPET\n• Tumor molecular testingdd\nif not previously done\n• Imaging studies as\nclinically indicateda,cc:\nC/A/P CT, MRI, PET/CT, or\nPET\n• Tumor molecular testingdd\nif not previously done\n• Imaging studies as\nclinically indicateda,cc:\nC/A/P CT, MRI, PET/CT, or\nPET\n• Tumor molecular testingdd\nif not previously done\nRising CA-125,\nno previous\nchemotherapy\nor\nClinical relapse,\nno previous\nchemotherapy\nClinical relapse,\nprevious\nchemotherapy\nSerially rising\nCA-125, previous\nchemotherapy\n• Visits every 2–4 mo for 2 y, then\n3–6 mo for 3 y, then annually after\n5 y\n• Physical exam including pelvis\nexam as clinically indicated\n• Imaging as clinically indicateda\n(eg, C/A/P CT, chest CT, A/P MRI,", "section": "Primary Peritoneal Cancer", "page_from": 13, "page_to": 13, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "e552ab993202546c349b8886b4c21bb54a7a3793ecd1112dfd8e316974b3da44"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000047", "text": "3–6 mo for 3 y, then annually after\n5 y\n• Physical exam including pelvis\nexam as clinically indicated\n• Imaging as clinically indicateda\n(eg, C/A/P CT, chest CT, A/P MRI,\nPET/MRI, PET/CT) (skull base to\nmid-thigh)\n• CBC and chemistry profile as\nindicated\n• CA-125aa or other tumor markers\nif initially elevated\n• Refer for genetic risk evaluation, if\nnot previously donef\n• Long-term wellness care\n(See NCCN Guidelines for\nSurvivorship)\nPrimary Treatment\n(OV-1)\nDelay treatment until\nclinical relapse\nor\nImmediate treatment\nfor recurrent disease\n(category 2B)n\nTherapy for Persistent\nDisease or Recurrence\n(OV-7)\nbb Consider symptom management and best supportive care. See NCCN Guidelines\nfor Palliative Care. Refer for palliative care assessment, if appropriate.\ncc Surveillance imaging may be indicated when tumor markers are considered\nunreliable, the physical exam is unreliable, and/or there is a high risk of recurrence.\ndd Validated molecular testing should be performed in a CLIA-approved facility using\nthe most recent available tumor tissue. Tumor molecular analysis is recommended\nto include, at a minimum, tests to identify potential benefit from targeted therapeutics", "section": "Primary Peritoneal Cancer", "page_from": 13, "page_to": 13, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "9e0ca9bd3bbd2f614120d9e15e48dd2bcb6f4c8773d9e7816b17ee0cfca9526a"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000048", "text": "the most recent available tumor tissue. Tumor molecular analysis is recommended\nto include, at a minimum, tests to identify potential benefit from targeted therapeutics\nthat have tumor-specific or tumor-agnostic benefit including, but not limited to, HER2\nstatus (by IHC), BRCA1/2, HRD status, microsatellite instability (MSI), mismatch\nrepair (MMR), tumor mutational burden (TMB), BRAF, FRα (FOLR1), RET, and NTRK\nif prior testing did not include these markers. More comprehensive testing may be\nparticularly important in LCOC with limited approved therapeutic options (OV-B).\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "Primary Peritoneal Cancer", "page_from": 13, "page_to": 13, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "48dbb418914f4210e0bc8cca386345e81a1a016fbf1a3ecd73b75cfed9acfba4"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000049", "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nEpithelial Ovarian Cancer/Fallopian Tube Cancer/\nPrimary Peritoneal Cancer\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nOV-7\nDISEASE STATUSf,dd,ee\nPlatinum-resistant diseaseff:\nProgression on primary,\nmaintenance or recurrence therapy\nor\nStable or persistent disease\n(if not on maintenance therapy)\nor\nComplete remission and relapse <6\nmo after completing chemotherapy\nPlatinum-sensitive diseaseff:\nComplete remission\nand relapse ≥6 mo\nafter completing prior\nchemotherapy\nf See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian,\nPancreatic, and Prostate and NCCN Guidelines for Genetic/Familial High-Risk Assessment:\nColorectal, Endometrial, and Gastric.\nn See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D).\ndd Validated molecular testing should be performed in a CLIA-approved facility using", "section": "Primary Peritoneal Cancer", "page_from": 14, "page_to": 14, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "d0caeae18d4f0a0246e0662c8fdc4227b4928ee99438563970e318d2a61b0f82"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000050", "text": "n See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D).\ndd Validated molecular testing should be performed in a CLIA-approved facility using\nthe most recent available tumor tissue. Tumor molecular analysis is recommended to\ninclude, at a minimum, tests to identify potential benefit from targeted therapeutics that\nhave tumor-specific or tumor-agnostic benefit including, but not limited to, HER2 status\n(by IHC), BRCA1/2, HRD status, MSI, MMR, TMB, BRAF, FRα (FOLR1), RET, and\nNTRK if prior testing did not include these markers. More comprehensive testing may be\nparticularly important in LCOC with limited approved therapeutic options (OV-B).\nee Tumor molecular testing prior to initiation of therapy for persistent/recurrent disease, if\nnot previously done.\nBest supportive care (See NCCN Guidelines for Palliative Care)\nand/or\nRecurrence therapy (OV-C, 9 of 12)n,jj,kk\nTHERAPY FOR PERSISTENT DISEASE OR RECURRENCEn,gg,hh,ii\nff Definitions of platinum-sensitive and platinum-resistant disease\nrepresent a spectrum of disease; clinical judgment and flexibility should\nbe utilized in determining treatment options.", "section": "Primary Peritoneal Cancer", "page_from": 14, "page_to": 14, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "0540025dd094ada1a4d276ed1572e4bf25ba47bd48131842afe18da765865597"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000051", "text": "ff Definitions of platinum-sensitive and platinum-resistant disease\nrepresent a spectrum of disease; clinical judgment and flexibility should\nbe utilized in determining treatment options.\ngg Data are limited on primary and maintenance therapy for recurrent/\npersistent LCOC.\nhh During and after treatment for recurrence, patients should be evaluated\nas indicated with tumor markers and repeat imaging (with modalities\npreviously used) to document response and/or disease status.\nii Ancillary Palliative Surgical Procedures (OV-A 4 of 4).\njj Patients who do not respond and progress on two consecutive regimens\nwithout evidence of clinical benefits have diminished likelihood of\nbenefitting from additional therapy (Griffiths RW, et al. Int J Gynecol\nCancer 2011;21:58-65). Decisions to offer clinical trials, supportive care,\nor additional therapy should be made on an individual basis.\nkk Localized radiation therapy (RT) can be considered to palliate\nsymptoms and/or for oligometastatic disease.\nOV-8\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.", "section": "Primary Peritoneal Cancer", "page_from": 14, "page_to": 14, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "4c49c5a39a8f2314f8a093b2ec3337c1eb2d867d608a5ca3a9c465948fa21f95"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000052", "text": "OV-8\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "Primary Peritoneal Cancer", "page_from": 14, "page_to": 14, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "0a187c6e8279dceaf4800bea0351534e7a71cb689899af4ef1f4fd6433d98b96"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000053", "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nEpithelial Ovarian Cancer/Fallopian Tube Cancer/\nPrimary Peritoneal Cancer\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nOV-8\nDISEASE STATUSf,dd,ee\nPlatinum-\nsensitive\ndiseaseff:\nComplete\nremission and\nrelapse ≥6 mo\nafter completing\nprior\nchemotherapy\nRadiographic\nand/or clinical\nrelapse\nBiochemical\nrelapse (rising\nCA-125 and no\nradiographic\nevidence of\ndisease)\nf See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic,\nand Prostate and NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal,\nEndometrial, and Gastric.\nj Principles of Surgery (OV-A).\nk Principles of Pathology (OV-B).\nn See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D).\ndd Validated molecular testing should be performed in a CLIA-approved facility using the", "section": "Primary Peritoneal Cancer", "page_from": 15, "page_to": 15, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "763b8dabed2d805aca8d860753cd2cdd162dd9e36d0bbab9c3966422983bfc5e"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000054", "text": "n See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D).\ndd Validated molecular testing should be performed in a CLIA-approved facility using the\nmost recent available tumor tissue. Tumor molecular analysis is recommended to include,\nat a minimum, tests to identify potential benefit from targeted therapeutics that have tumor-\nspecific or tumor-agnostic benefit including, but not limited to, HER2 status (by IHC),\nBRCA1/2, HRD status, MSI, MMR, TMB, BRAF, FRα (FOLR1), RET, and NTRK if prior\ntesting did not include these markers. More comprehensive testing may be particularly\nimportant in LCOC with limited approved therapeutic options (OV-B).\nee Tumor molecular testing prior to initiation of therapy for persistent/recurrent disease, if not\npreviously done.\nff Definitions of platinum-sensitive and platinum-resistant disease represent a spectrum of\ndisease; clinical judgment and flexibility should be utilized in determining treatment options.\nCombination platinum-\nbased chemotherapy,n\npreferred for first\nrecurrence (category 1)\nor\nRecurrence therapyn,kk\nand/or\nBest supportive care\n(See NCCN Guidelines\nfor Palliative Care)\nConsider\nsecondary\ncytoreductive", "section": "Primary Peritoneal Cancer", "page_from": 15, "page_to": 15, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "b45ae1a36546ee9a0513047c3f26524687ff56a672b14c867675ac9c1c4cd09c"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000055", "text": "based chemotherapy,n\npreferred for first\nrecurrence (category 1)\nor\nRecurrence therapyn,kk\nand/or\nBest supportive care\n(See NCCN Guidelines\nfor Palliative Care)\nConsider\nsecondary\ncytoreductive\nsurgeryj,k\nImmediate platinum-based\nrecurrence therapyn (category 2B)\nand/or\nBest supportive care (See NCCN\nGuidelines for Palliative Care)\nRECURRENCE THERAPY FOR PLATINUM-SENSITIVE DISEASEn,gg,hh,ii\nMaintenance therapy (if PR or CR)\n• Useful in certain circumstances:\n\u0017Continue bevacizumab if previously\ntreated with chemotherapy +\nbevacizumab;\nor\n\u0017PARPi therapy (for those with BRCA\n1/2 mutation)ll:\n ◊If not previously used (category 1)\n ◊If disease has not progressed\nduring prior PARPi treatment\nor\nObserve\ngg Data are limited on primary and maintenance therapy for recurrent/persistent LCOC.\nhh During and after treatment for recurrence, patients should be evaluated as indicated with\ntumor markers and repeat imaging (with modalities previously used) to document response\nand/or disease status.\nii Ancillary Palliative Surgical Procedures (OV-A 4 of 4).\nkk Localized RT can be considered to palliate symptoms and/or for oligometastatic disease.", "section": "Primary Peritoneal Cancer", "page_from": 15, "page_to": 15, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "44df4552a910912ee6ab6262a084be496fc0f3b99b04b3ab8a93c7f3e0bcda86"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000056", "text": "and/or disease status.\nii Ancillary Palliative Surgical Procedures (OV-A 4 of 4).\nkk Localized RT can be considered to palliate symptoms and/or for oligometastatic disease.\nll PARPi options include niraparib, olaparib, or rucaparib in patients with BRCA-mutated\nplatinum-sensitive disease who have completed two or more lines of platinum-based\ntherapy. Based on FDA indication, niraparib is limited to those with a deleterious or\nsuspected deleterious germline BRCA mutation. Based on FDA indications, olaparib and\nrucaparib are limited to those with a deleterious or suspected deleterious BRCA mutation\n(germline or somatic). Caution should be used when using maintenance PARPi for longer\nthan 24 months. There are limited data on the use of a maintenance PARPi in patients who\npreviously received a PARPi. Combination bevacizumab/PARPi is not recommended for\nmaintenance after recurrence therapy.\nMonitoring/\nFollow-up\n(OV-6)\nDelay treatment until\nradiographic and/or clinical\nrelapse\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.", "section": "Primary Peritoneal Cancer", "page_from": 15, "page_to": 15, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "57d1f58ec9adcc22656d5d3d4cfaa83f6b52a73ae1c548c39508074eacd0fe21"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000057", "text": "relapse\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "Primary Peritoneal Cancer", "page_from": 15, "page_to": 15, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "b2c5d3ab863de3c6ebb2e838b5334677f695b2460fc0a990b6cd5a6effad48a1"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000058", "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nLess Common Ovarian Cancers\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nLCOC-1\na WHO Histologic Classification (OV-E).\nb Due to emerging therapeutics for LCOC, there is value in identifying potential pathways for rare cancers and it may be useful for clinical trial recruitment. Tumor\nmolecular testing can be considered, if not previously done, as it may help guide treatment. There are limited data in these cancers given their infrequency and it will\nbe difficult to acquire prospective data. Individualized treatment may be the best treatment for these rare tumors. [Committee on the State of the Science in Ovarian\nCancer, et al. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington (DC): National Academies Press (US) Copyright 2016 by the National\nAcademy of Sciences. All rights reserved; 2016.]\nc Principles of Surgery (OV-A).", "section": "Less Common Ovarian Cancers", "page_from": 16, "page_to": 16, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "aa40c2ded927b5dc16b56f9351914d867a29c7d1062ad66a2ac2c3c4f9a6c5bf"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000059", "text": "Academy of Sciences. All rights reserved; 2016.]\nc Principles of Surgery (OV-A).\nd Principles of Pathology (OV-B).\ne LCOC are typically diagnosed after surgery. See Workup (OV-1).\nDIAGNOSISa,b\nSurgeryc,d and histologic diagnosisb,e\nMalignant germ cell tumors\nLCOC-12 to\nLCOC-14\nOvarian serous borderline epithelial\ntumors (low malignant potential [LMP])\nLCOC-8 to\nLCOC-10\nMalignant sex cord-stromal tumors\nLCOC-11\nCarcinosarcoma\n(malignant mixed Müllerian tumor [MMMT])\nLCOC-2\nClear cell carcinoma of the ovary\nLCOC-3\nMucinous neoplasms of the ovary\nLCOC-4\nLow-grade serous carcinoma\nLCOC-6\nLCOC-5\nGrade 1 endometrioid carcinoma\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "Less Common Ovarian Cancers", "page_from": 16, "page_to": 16, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "b7f91da3966358f0950a834e4d43831d98cde0b41fd17127e2dfea8b6ea9dfb5"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000060", "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nCarcinosarcoma (Malignant Mixed Müllerian Tumors)\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nLCOC-2\nPATHOLOGIC DIAGNOSISa\nADJUVANT TREATMENTf\nCarcinosarcoma (MMMTs)\nof the ovaryg,h,i\nStage I\nStage\nII–IV\nIV paclitaxel/carboplatin every\n3 weeks (preferred)f\nor\nOther systemic therapy\n• Stage I (OV-C, 5 of 12)\n• Stage II–IV (OV-C, 6 of 12)\na WHO Histologic Classification (OV-E).\nf See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D).\ng If not previously done, consider surgical staging and resection of residual disease (OV-3).\nh If not previously done, consider germline and somatic testing (OV-B).\ni Germline and somatic BRCA1/2 status informs maintenance therapy. In the absence of a BRCA1/2 mutation, HRD status may provide information on the magnitude of", "section": "NCCN Guidelines Index", "page_from": 17, "page_to": 17, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "e9d2712fa1a523451cdf276e922b2d7815ceb9effa17868c0f9e69a79d336e00"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000061", "text": "i Germline and somatic BRCA1/2 status informs maintenance therapy. In the absence of a BRCA1/2 mutation, HRD status may provide information on the magnitude of\nbenefit of PARPi therapy. For PARPi therapy in advanced stage disease, include measure of HR (OV-B).\nj Data are limited on primary and maintenance therapy for recurrent/persistent LCOC.\nMONITORING/\nFOLLOW-UP\nMonitoring/\nFollow-up\n(including\ntumor testing)\nand\nRecurrence\ntherapyj\n(OV-6)\nIf known BRCA1/2\nmutation, consider\nmaintenance therapy\n(post-primary\ntherapy) (OV-5)\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "NCCN Guidelines Index", "page_from": 17, "page_to": 17, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "6bcc8efca5c9f185dc7ee980fd4f075db47a74bef30c883623e3d269f0bcf6f0"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000062", "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nClear Cell Carcinoma of the Ovary\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nClear cell carcinoma\nof the ovaryg,h,i\nStage\nIC2– IC3\nStage IA\nIB, IC1\nStage II–IV\nIV platinum-based therapy\n(see primary regimens for stage I disease\n[OV-C, 5 of 12])\nIV platinum-based therapy\n(see primary regimens for stage I disease\n[OV-C, 5 of 12])\nor\nObserveg\nSystemic therapy\n(OV-C, 6 of 12)\nLCOC-3\nPATHOLOGIC\nDIAGNOSISa\nADJUVANT TREATMENTf\nMONITORING/\nFOLLOW-UP\nMonitoring/Follow-up\n(including tumor testing)\nand\nRecurrence therapyj\n(OV-6)\nIf known BRCA1/2\nmutation, consider\nmaintenance therapy\n(post-primary therapy)\n(OV-5)\na WHO Histologic Classification (OV-E).\nf See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D).\ng If not previously done, consider surgical staging and resection of residual disease (OV-3).", "section": "Clear Cell Carcinoma of the Ovary", "page_from": 18, "page_to": 18, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "883b614a3589c0845186a23f46ecd1e95d7bc40dc4043dcfc1360fe352bf6de6"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000063", "text": "f See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D).\ng If not previously done, consider surgical staging and resection of residual disease (OV-3).\nh If not previously done, consider germline and somatic testing (OV-B).\ni Germline and somatic BRCA1/2 status informs maintenance therapy. In the absence of a BRCA1/2 mutation, HRD status may provide information on the magnitude\nof benefit of PARPi therapy. For PARPi therapy in advanced stage disease, include measure of HR (OV-B).\nj Data are limited on primary and maintenance therapy for recurrent/persistent LCOC.\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "Clear Cell Carcinoma of the Ovary", "page_from": 18, "page_to": 18, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "5254a9c99783bb3db0bfa2a350245d0201e965e75c1d923a27ee2a5d4cf09c3e"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000064", "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nMucinous Neoplasms of the Ovary\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nStage IA\ncarcinoma\nStage IC\ncarcinoma\nStage II–IV\ncarcinoma\nMucinous\nneoplasms of\nthe ovaryd,g,h\nIf not previously done:\n• GI evaluationk\n• Carcinoembryonic\nantigen (CEA)\n• CA 19-9\nObserve\nSystemic therapy (OV-C, 6 of 12)f\na WHO Histologic Classification (OV-E).\nd Principles of Pathology (OV-B).\nf See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D).\ng If not previously done, consider surgical staging and resection of residual disease (OV-3).\nh If not previously done, consider germline and somatic testing (OV-B).\nj Data are limited on primary and maintenance therapy for recurrent/persistent LCOC.", "section": "Mucinous Neoplasms of the Ovary", "page_from": 19, "page_to": 19, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "b21b1a71cba2aaa6045c0882fb2627581bb0997218922769dfdfd4a15faab8fe"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000065", "text": "h If not previously done, consider germline and somatic testing (OV-B).\nj Data are limited on primary and maintenance therapy for recurrent/persistent LCOC.\nk Consider additional testing, including but not limited to upper and lower endoscopic evaluation, to aid in the identification of metastatic GI malignancies versus primary\nmucinous ovarian cancer.\nADDITIONAL WORKUP\nLCOC-4\nPATHOLOGIC\nDIAGNOSISa\nBorderline\nObserve\nADJUVANT TREATMENTf\nMonitoring/\nFollow-up\n(including\ntumor testing)\nand\nRecurrence\ntherapyj\n(OV-6)\nMONITORING/\nFOLLOW-UP\nStage IB\ncarcinoma\nExpansile\nInfiltrative\nObserve\nor\nSystemic therapy\n(OV-C, 5 of 12)f\nObserve\nExpansile\nInfiltrative\nSystemic therapy\n(OV-C, 5 of 12)f\nExpansile\nInfiltrative\nObserve\nor\nSystemic therapy\n(OV-C, 5 of 12)f\nSystemic therapy\n(OV-C, 5 of 12)f\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "Mucinous Neoplasms of the Ovary", "page_from": 19, "page_to": 19, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "2608a25c56b818e0222a0890c92f1d8dbb884ba3adc88f50d6a609dfa306abb1"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000066", "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nGrade 1 Endometrioid Carcinoma\nNCCN Guidelines Index\nTable of Contents\nDiscussion\na WHO Histologic Classification (OV-E).\nf See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions\n(OV-D).\ng If not previously done, consider surgical staging and resection of residual disease\n(OV-3).\nh If not previously done, consider germline and somatic testing (OV-B).\nj Data are limited on primary and maintenance therapy for recurrent/persistent\nLCOC.\nl MSI/MMR testing is recommended for all patients with endometrioid carcinoma.\nm Other hormonal therapy options include: aromatase inhibitors (ie, anastrozole,\nexemestane), leuprolide acetate, goserelin acetate, and tamoxifen.\nLCOC-5\nGrade 1\nendometrioid\ncarcinomag,h,l\nStage IA–IB\nStage IC\nStage II–IV\nObserveg\nObserveg (category 2B)\nor\nSystemic therapy (OV-C, 5 of 12)f\n• Chemotherapyf\n  or\n• Hormonal therapyf", "section": "Grade 1 Endometrioid Carcinoma", "page_from": 20, "page_to": 20, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "a7df47c2802d874942776881244437f934e1697a5fb7741a6c13b45f25ae475b"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000067", "text": "LCOC-5\nGrade 1\nendometrioid\ncarcinomag,h,l\nStage IA–IB\nStage IC\nStage II–IV\nObserveg\nObserveg (category 2B)\nor\nSystemic therapy (OV-C, 5 of 12)f\n• Chemotherapyf\n  or\n• Hormonal therapyf\n(category 2B)\nSystemic therapy (OV-C, 6 of 12)f\n• Chemotherapyf\n  or\n• Hormonal therapyf\n(category 2B)\nObserve\nor\nMaintenance letrozole\n(category 2B) or other\nhormonal therapy\n(category 2B)m\nObserve\nor\nMaintenance letrozole\n(category 2B) or other\nhormonal therapy\n(category 2B)m\nPATHOLOGIC\nDIAGNOSISa\nMONITORING/\nFOLLOW-UP\nADJUVANT TREATMENT\nMonitoring/Follow-up\n(including tumor testing)\nand\nRecurrence therapyj\n(OV-6)\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "Grade 1 Endometrioid Carcinoma", "page_from": 20, "page_to": 20, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "372eb153ca981cec6a3090f0e61eacb28610e8d113add51c441822d647a6b34a"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000068", "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nLow-Grade Serous Carcinoma\nNCCN Guidelines Index\nTable of Contents\nDiscussion\na WHO Histologic Classification (OV-E).\nf See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D).\ng If not previously done, consider surgical staging and resection of residual disease (OV-3).\nh If not previously done, consider germline and somatic testing (OV-B).\nn Other hormonal therapy options include: aromatase inhibitors (ie, anastrozole, exemestane), leuprolide acetate, and goserelin acetate.\nADJUVANT TREATMENT\nLCOC-6\nLow-grade\nserous\ncarcinomag,h\nStage\nIA–IB\nStage IC\nStage\nII–IV\nObserveg\nMaintenance letrozole\nor\nOther hormonal therapy\n(category 2B)n\nPATHOLOGIC\nDIAGNOSISa\nMONITORING/\nFOLLOW-UP\nSystemic therapy (OV-C, 6 of 12)f\n• Chemotherapyf\n  or\n• Hormonal therapyf\n(category 2B)\nObserveg (category 2B)\nor\nSystemic therapy (OV-C, 5 of 12)f\n• Chemotherapyf", "section": "Low-Grade Serous Carcinoma", "page_from": 21, "page_to": 21, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "1306a8c8e1e9650aa94c0f789e81dc7bc16be9d185224d3b68718a37522e769c"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000069", "text": "DIAGNOSISa\nMONITORING/\nFOLLOW-UP\nSystemic therapy (OV-C, 6 of 12)f\n• Chemotherapyf\n  or\n• Hormonal therapyf\n(category 2B)\nObserveg (category 2B)\nor\nSystemic therapy (OV-C, 5 of 12)f\n• Chemotherapyf\n  or\n• Hormonal therapyf\n(category 2B)\nObserve\nor\nMaintenance letrozole\nor\nOther hormonal therapy\n(category 2B)n\nMonitoring/\nFollow-\nup for\nRecurrent\nDisease\n(LCOC-7)\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "Low-Grade Serous Carcinoma", "page_from": 21, "page_to": 21, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "db6ce864451251d29e62b15045d3593c3aee05d318cd3f5bbe9b3fd804728894"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000070", "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nLow-Grade Serous Carcinoma\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nMONITORING/FOLLOW-\nUP FOR RECURRENCE\nRECURRENCE THERAPYs\n• Visits every 2–4 mo for 2 y, then 3–6 mo for 3 y, then\nannually after 5 y\n• Physical exam including pelvic exam as clinically\nindicated\n• Tumor molecular testing if not previously doneo\n• Imaging as clinically indicatedp (eg, C/A/P CT, chest\nCT, A/P MRI, PET/CT, or PET/MRI) (skull base to mid-\nthigh)\n• CBC and chemistry profile as indicated\n• CA-125q or other tumor markers if initially elevated\n• Refer for genetic risk evaluation, if not previously\ndoner\n• Long-term wellness care (See NCCN Guidelines for\nSurvivorship)\nRecurrent\ndiseaset\nHormonal therapyu\nor\nChemotherapy (if not previously used), see OV-C (6 of 12)\nor\nSystemic therapyf,v\n• For platinum-sensitive disease, see OV-C (8 of 12)", "section": "Low-Grade Serous Carcinoma", "page_from": 22, "page_to": 22, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "4ddb74a647d83e4c58e678aaf0c4c134c70ff85f7d9866f507ce33717f95ef33"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000071", "text": "Survivorship)\nRecurrent\ndiseaset\nHormonal therapyu\nor\nChemotherapy (if not previously used), see OV-C (6 of 12)\nor\nSystemic therapyf,v\n• For platinum-sensitive disease, see OV-C (8 of 12)\n• For platinum-resistant disease, see OV-C (9 of 12)\nor\nObservation\nf See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions\n(OV-D).\no Validated molecular testing should be performed in a CLIA-approved facility\nusing the most recent available tumor tissue. Tumor molecular analysis is\nrecommended to include, at a minimum, tests to identify potential benefit from\ntargeted therapeutics that have tumor-specific or tumor-agnostic benefit including,\nbut not limited to, HER2 status (by IHC), BRCA1/2, HRD status, MSI, MMR,\nTMB, BRAF, FRα (FOLR1), RET, and NTRK if prior testing did not include these\nmarkers. More comprehensive testing may be particularly important in LCOC with\nlimited approved therapeutic options (OV-B).\np CT is performed with oral and iodinated IV contrast (unless contraindicated due\nto anaphylaxis or significant renal dysfunction) with or without rectal contrast. MRI\nis performed with gadolinium-based contrast agents (unless contraindicated due", "section": "Low-Grade Serous Carcinoma", "page_from": 22, "page_to": 22, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "3025222289e7aa799a234229ea2e667aeea92845f0cc0cb8615702743e7aef1d"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000072", "text": "to anaphylaxis or significant renal dysfunction) with or without rectal contrast. MRI\nis performed with gadolinium-based contrast agents (unless contraindicated due\nto anaphylaxis) and is preferred in select patients with renal dysfunction over CT.\nChest CT can be done with or without iodinated IV contrast.\nq There are data regarding the utility of CA-125 for monitoring of ovarian cancer\nafter completion of primary therapy. See The Society of Gynecologic Oncology\n(SGO) position statement and Discussion.\nr See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian,\nPancreatic, and Prostate and NCCN Guidelines for Genetic/Familial High-Risk\nAssessment: Colorectal, Endometrial, and Gastric.\ns There is no standard sequencing of drugs for recurrent disease. Considerations\ninclude prior therapies, disease burden, relative efficacy, and relative toxicity\nprofile.\nt Consider secondary cytoreduction in patients with long disease-free interval,\nisolated masses rather than diffuse carcinomatosis on imaging, and/or bowel\nobstruction.\nu An aromatase inhibitor (ie, letrozole, anastrozole, exemestane) is preferred", "section": "Low-Grade Serous Carcinoma", "page_from": 22, "page_to": 22, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "aeea59e3275ac22a743c3083980bcd1f4c4fa736a886b4b8715f72a1eec9d218"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000073", "text": "isolated masses rather than diffuse carcinomatosis on imaging, and/or bowel\nobstruction.\nu An aromatase inhibitor (ie, letrozole, anastrozole, exemestane) is preferred\nif not used previously. Fulvestrant, leuprolide acetate, or goserelin acetate is\nrecommended if an aromatase inhibitor was given previously.\nv Data are limited on maintenance therapy for recurrent/resistant LCOC. See OV-8\nfor maintenance options after platinum-based therapy, and patient selection\ncriteria.\nLCOC-7\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "Low-Grade Serous Carcinoma", "page_from": 22, "page_to": 22, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "e037f30f5d09031abbd3a4c46db7bdc3200b0b3d979905a69718fa1fad84398a"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000074", "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nOvarian Serous Borderline Epithelial Tumors\n(Low Malignant Potential)\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nLCOC-8\nPATHOLOGIC\nDIAGNOSISa\na WHO Histologic Classification (OV-E).\nc Principles of Surgery (OV-A).\nd Principles of Pathology (OV-B).\nw Chemotherapy (IV or IP) has not been shown to be beneficial in ovarian borderline epithelial tumors (LMP).\nx Standard recommendation includes a patient evaluation by a gynecologic oncologist.\nObserve\nSee adjuvant\noptions (LCOC-6)\nOvarian serous borderline\nepithelial tumors (LMP)a\nADJUVANT TREATMENTx\nPrior complete\nsurgical resectionc,d\nNo low-grade\nserous carcinoma\nPrior incomplete\nsurgical resectionc,d\nLow-grade serous\ncarcinomaw\nMonitoring/\nFollow-up\n(LCOC-10)\nLCOC-9", "section": "Ovarian Serous Borderline Epithelial Tumors", "page_from": 23, "page_to": 23, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "fbec0db40652ed97469cb33fb68d48100d9d6dfd55dba6746e14487c94b42bba"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000075", "text": "ADJUVANT TREATMENTx\nPrior complete\nsurgical resectionc,d\nNo low-grade\nserous carcinoma\nPrior incomplete\nsurgical resectionc,d\nLow-grade serous\ncarcinomaw\nMonitoring/\nFollow-up\n(LCOC-10)\nLCOC-9\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "Ovarian Serous Borderline Epithelial Tumors", "page_from": 23, "page_to": 23, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "6b61b66c33594eb49b86d20044415e1c376d4543a0d6644967482e1ac133e72b"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000076", "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nOvarian Serous Borderline Epithelial Tumors\n(Low Malignant Potential)\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nLCOC-9\nPATHOLOGIC\nDIAGNOSISa\na WHO Histologic Classification (OV-E).\nc Principles of Surgery (OV-A).\nd Principles of Pathology (OV-B).\np CT is performed with oral and iodinated IV contrast (unless contraindicated due\nto anaphylaxis or significant renal dysfunction) with or without rectal contrast. MRI\nis performed with gadolinium-based contrast agents (unless contraindicated due\nto anaphylaxis) and is preferred in select patients with renal dysfunction over CT.\nChest CT can be done with or without iodinated IV contrast.\nw Chemotherapy (IV or IP) has not been shown to be beneficial in ovarian\nborderline epithelial tumors (LMP).\nx Standard recommendation includes a patient evaluation by a gynecologic\noncologist.", "section": "Ovarian Serous Borderline Epithelial Tumors", "page_from": 24, "page_to": 24, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "4b642aa1d36c9ea4317f732dd56bea9a944673738a53b53d887dc890885880c5"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000077", "text": "w Chemotherapy (IV or IP) has not been shown to be beneficial in ovarian\nborderline epithelial tumors (LMP).\nx Standard recommendation includes a patient evaluation by a gynecologic\noncologist.\ny For pathologically proven ovarian borderline epithelial tumors, lymph node\nevaluation may be considered on a case-by-case basis.\nz In patients who underwent USO, consider completion surgery (eg, contralateral\nUSO, hysterectomy) after completion of childbearing (category 2B).\naa If patient is medically unfit, or for those with unresectable residual disease.\nResidual\ndisease\nsuspected after\nfirst procedure\nand/or on\nimaging\nNo residual disease\nremaining after first\nprocedure and/or on imaging\nOvarian\nserous\nborderline\nepithelial\ntumor (LMP),\nincomplete\nsurgical\nstaging,a\nor tumor\nreductive\nsurgery\nImagingp\nif not\npreviously\ndone\n• eg, C/A/P\nCT, chest\nCT, A/P\nMRI, PET/\nCT, PET/\nMRI\nObservez\nMonitoring/\nFollow-up\n(LCOC-10)\nLCOC-6\nOV-4\nADJUVANT TREATMENTx\nCompletion surgery (contralateral\nUSO, hysterectomy) and resection of\nresidual diseasey\nor\nFertility-sparing surgery (if fertility\ndesired)c,d and resection of residual\ndiseasey,z\nor\nConsider no surgical intervention for\nselect patientsaa", "section": "Ovarian Serous Borderline Epithelial Tumors", "page_from": 24, "page_to": 24, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "7d059d752bac221590cb0f6e34a54d28fe9e57b332a841c269973d448042b8a3"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000078", "text": "residual diseasey\nor\nFertility-sparing surgery (if fertility\ndesired)c,d and resection of residual\ndiseasey,z\nor\nConsider no surgical intervention for\nselect patientsaa\nBorderline on\nfinal pathology\nLow-grade\nserous\ncarcinoma on\nfinal pathologyw\nHigh-grade\nserous on final\npathologyw\nMonitoring/\nFollow-up\n(LCOC-10)\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "Ovarian Serous Borderline Epithelial Tumors", "page_from": 24, "page_to": 24, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "e25b75e98370f4b3e53fbea3ab81de2efdaf376962b5447f5a272c6b65238162"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000079", "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nOvarian Serous Borderline Epithelial Tumors\n(Low Malignant Potential)\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nLCOC-10\nMONITORING/FOLLOW-UP\np CT is performed with oral and iodinated IV contrast (unless contraindicated due\nto anaphylaxis or significant renal dysfunction) with or without rectal contrast. MRI\nis performed with gadolinium-based contrast agents (unless contraindicated due\nto anaphylaxis) and is preferred in select patients with renal dysfunction over CT.\nChest CT can be done with or without iodinated IV contrast.\nq There are data regarding the utility of CA-125 for monitoring of ovarian cancer\nafter completion of primary therapy. See The Society of Gynecologic Oncology\n(SGO) position statement and Discussion.\nw Chemotherapy (IV or IP) has not been shown to be beneficial in ovarian\nborderline epithelial tumors (LMP).\nSurgical\nevaluation", "section": "Ovarian Serous Borderline Epithelial Tumors", "page_from": 25, "page_to": 25, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "cf219eab030b17718255b9922555a4f807b12af6d9e55a24a2e155da7374f70a"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000080", "text": "(SGO) position statement and Discussion.\nw Chemotherapy (IV or IP) has not been shown to be beneficial in ovarian\nborderline epithelial tumors (LMP).\nSurgical\nevaluation\n+ debulking\nif appropriate\n• Visits every 3–12 mo for up to 5 y,\nthen as clinically indicated\n• Physical exam including pelvic exam\nas clinically indicated\n• CA-125q or other tumor markers every\nvisit if initially elevated\n• CBC, chemistry profile as indicated\n• Imagingp as clinically indicated: eg\nC/A/P CT, chest CT, A/P MRI, PET/CT,\nor PET/MRI (skull base to mid-thigh)\n• Ultrasound as indicated for patients\nwith fertility-sparing surgery\nTreatment as epithelial\novarian cancerw (OV-4)\nObserve\nHigh-grade invasive\ncarcinoma\nLow-grade invasive\ncarcinoma\nNoninvasive disease\nClinical\nrelapse\nRECURRENCE THERAPY\nRECURRENT DISEASE\nSee appropriate\nLCOC page based on\nhistologyw (LCOC-1)\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "Ovarian Serous Borderline Epithelial Tumors", "page_from": 25, "page_to": 25, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "17e0af2b89ebf61df0e0bae07ce1109573c6004190faf06ff3d0f73d99ce5586"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000081", "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nMalignant Sex Cord-Stromal Tumors\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nLCOC-11\nCLINICAL PRESENTATION/\nDIAGNOSIS\nADJUVANT\nTREATMENT\nRECURRENCE\nTHERAPY\nMalignant sex\ncord-stromal\ntumorsa\nDisease\nclinically\nconfined\nto ovary,\nfertility\ndesired\nAll others\nStage I\nLow risk\nStage II–IV\nFertility-\nsparing\nsurgery with\ncomplete\nstagingc,d,bb\nStage I, high risk\n(eg, ruptured\nstage IC or poorly\ndifferentiated stage I)\nor\nIntermediate risk\n(eg, heterologous\nelements)\nObservecc (category 2B)\nor\nConsider platinum-based\nchemotherapydd,ee\n(category 2B)\nPlatinum-based\nchemotherapydd,ee\nor\nRT for limited\ndisease (category 2B)\nIf clinical relapse:\nConsider\nsecondary\ncytoreductive\nsurgery\nor\nRecurrence\ntherapyee,ff\nComplete\nstagingc,d,bb\nSurveillance\n(LCOC-B)\nObservecc\na WHO Histologic Classification (OV-E).\nc Principles of Surgery (OV-A).", "section": "Malignant Sex Cord-Stromal Tumors", "page_from": 26, "page_to": 26, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "ee44b3a31c579396fbe1973453e94f49ea87c1fadaaeba9e9d647b05524bea05"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000082", "text": "Consider\nsecondary\ncytoreductive\nsurgery\nor\nRecurrence\ntherapyee,ff\nComplete\nstagingc,d,bb\nSurveillance\n(LCOC-B)\nObservecc\na WHO Histologic Classification (OV-E).\nc Principles of Surgery (OV-A).\nd Principles of Pathology (OV-B).\nbb Lymphadenectomy may be omitted.\ncc Inhibin levels can be followed for granulosa cell tumors.\nSurveillance\n(LCOC-B)\ndd Acceptable options include paclitaxel/carboplatin (preferred), EP (etoposide, cisplatin), or BEP\n(bleomycin, etoposide, cisplatin) (category 2B).\nee See Principles of Systemic Therapy (OV-C) and Systemic Therapy Regimens for Malignant Germ\nCell/Sex Cord-Stromal Tumors (LCOC-A).\nff Localized RT can be considered to palliate symptoms and/or for oligometastatic disease.\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "Malignant Sex Cord-Stromal Tumors", "page_from": 26, "page_to": 26, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "bee8457c6cce94ddbfd700dcd251ca9c8f72939ff76b25b140a3639b7c75c31a"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000083", "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nMalignant Germ Cell Tumors\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nLCOC-12\nTREATMENTx\nMalignant\ngerm cell\ntumors\nInitial\nsurgerygg\nPrior\nsurgerygg\nFertility-sparing surgery and\ncomprehensive staging (OV-A)\nComplete staging surgery\n(OV-A)\nFertility desired, then fertility-sparing\nsurgery and comprehensive staging;\nfertility not desired, then completion\nstaging surgery (OV-A)\nConsider observation (category 2B) with close\nmonitoring of tumor markers until normalization\n(LCOC-B)hh\nConsider observation (category 2B) (LCOC-B)\nDysgerminoma\nor\nGrade 1 immature\nteratoma\nEmbryonal,\nendodermal sinus\ntumor (yolk sac\ntumor), grade 2–3\nimmature teratoma,\nnongestational\nchoriocarcinoma, or\nmixed histology\nPositive imaging\nand positive\ntumor markers\nPositive\nimaging and\npositive tumor\nmarkers\nNegative imaging\nand positive\ntumor markers\nNegative imaging and", "section": "Malignant Germ Cell Tumors", "page_from": 27, "page_to": 27, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "0c0a836fb52268ce7dd44ac9e8bf569b746b6f1612d7da91a1a66530115dab30"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000084", "text": "choriocarcinoma, or\nmixed histology\nPositive imaging\nand positive\ntumor markers\nPositive\nimaging and\npositive tumor\nmarkers\nNegative imaging\nand positive\ntumor markers\nNegative imaging and\npositive or negative\ntumor markers\nNegative imaging\nand negative\ntumor markers\nFertility desired\nFertility not desired\nIncompletely\nstaged:\nImaging if not\npreviously\ndonep (eg,\nC/A/P CT, chest\nCT, A/P MRI,\nPET/CT, or\nPET/MRI)\nTreatment\n(LCOC-13)\nTreatment\n(LCOC-13)\nTreatment\n(LCOC-13)\nFertility desired, then fertility-sparing\nsurgery and comprehensive staging;\nfertility not desired, then completion\nstaging surgery with possible tumor\nreductive surgery (OV-A)\nor\nChemotherapy (LCOC-13)\np CT is performed with oral and iodinated IV contrast (unless contraindicated due to\nanaphylaxis or significant renal dysfunction) with or without rectal contrast. MRI is\nperformed with gadolinium based contrast agents (unless contraindicated due to\nanaphylaxis) and is preferred in select patients with renal dysfunction over CT. Chest\nCT can be done with or without iodinated IV contrast.\nx Standard recommendation includes a patient evaluation by a gynecologic oncologist.", "section": "Malignant Germ Cell Tumors", "page_from": 27, "page_to": 27, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "b72849dc7fb39aedbfad176bb27ab8e4d00b936e12ada6c68cdaf1e15bc7ace8"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000085", "text": "CT can be done with or without iodinated IV contrast.\nx Standard recommendation includes a patient evaluation by a gynecologic oncologist.\ngg Surgical principles for pediatric/young adult patients may differ from those for adult\npatients. See Principles of Surgery (OV-A).\nhh Repeat imaging if tumor markers plateau at significant abnormal level or rise. If\nimaging positive, follow pathway above for positive imaging and positive tumor\nmarkers.\nCLINICAL PRESENTATION/\nDIAGNOSIS\nCompletely staged\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "Malignant Germ Cell Tumors", "page_from": 27, "page_to": 27, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "a336d36b2819b895fd7303796e74026140dbf1e7aa135ff33d1757794219758b"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000086", "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nMalignant Germ Cell Tumors\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nLCOC-13\nADJUVANT TREATMENT\nMONITORING/\nFOLLOW-UP\nTHERAPY FOR RECURRENT/\nPERSISTENT DISEASEff\nPATHOLOGIC\nDIAGNOSISa\nAny stage\nembryonal\ntumorii\nor\nAny stage\nendodermal\nsinus tumor (yolk\nsac tumor)ii\nor\nStage II–IV\ndysgerminoma\nor\nStage I, grade\n2 or 3 or Stage\nII–IV immature\nteratoma\nor\nAny stage\nnongestational\nchoriocarcinoma\nStage I\ndysgerminomaii\nor\nStage I, grade 1\nimmature\nteratomaii\nChemotherapyjj\nLCOC-14\nC/A/P CTp or MRI as\nclinically indicated\nResidual\ntumor on\nradiographic\nimaging;\nmarkers\nnormalkk\nPersistently\nelevated markerskk\nwith definitive\nresidual disease\nBiopsy\nor\nConsider\nsurgical\nresection\nor\nObserve\n(Surveillance\n[LCOC-B])\nNecrotic\ntissue\nBenign\nteratoma\nResidual\nmalignancy\nObserve\nSurveillance (LCOC-B)\nComplete\nclinical\nresponse\nTIP (paclitaxel/ifosfamide/\ncisplatin)", "section": "Malignant Germ Cell Tumors", "page_from": 28, "page_to": 28, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "b72d45c6d9b1f7fd43fa1e1f373af6ff951e5b003f17f3657319fb24a3a097ca"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000087", "text": "resection\nor\nObserve\n(Surveillance\n[LCOC-B])\nNecrotic\ntissue\nBenign\nteratoma\nResidual\nmalignancy\nObserve\nSurveillance (LCOC-B)\nComplete\nclinical\nresponse\nTIP (paclitaxel/ifosfamide/\ncisplatin)\nor\nHigh-dose chemotherapyll +\nhematopoietic cell transplant\n(HCT) (strongly recommend\nreferral to tertiary care center for\npotentially curative regimen)\na WHO Histologic Classification (OV-E).\np CT is performed with oral and iodinated IV contrast (unless contraindicated due to anaphylaxis or significant renal dysfunction) with or without rectal contrast. MRI is performed with\ngadolinium-based contrast agents (unless contraindicated due to anaphylaxis) and is preferred in select patients with renal dysfunction over CT. Chest CT can be done with or without\niodinated IV contrast.\nff Localized RT can be considered to palliate symptoms and/or for oligometastatic disease.\nii Pediatric/adolescent patients with the following clinical presentations may consider observation or chemotherapy as treatment options: stage IA, IB dysgerminoma; stage IA, grade 1", "section": "Malignant Germ Cell Tumors", "page_from": 28, "page_to": 28, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "9005d4916520d651fb21bd9ee325400b299274c76998b77be2f55df8774d4778"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000088", "text": "ii Pediatric/adolescent patients with the following clinical presentations may consider observation or chemotherapy as treatment options: stage IA, IB dysgerminoma; stage IA, grade 1\nimmature teratoma; stage IA embryonal carcinomas; or stage IA yolk sac tumors. Consultation with a pediatric oncologist for pediatric/adolescent patients is recommended.\njj Primary Systemic Therapy Regimens for Malignant Germ Cell Tumors (LCOC-A).\nkk See OV-1 for markers.\nll High-dose chemotherapy regimens vary among institutions. Some patients are potentially curable with HCT. Patients with potentially curable recurrent germ cell disease should be\nreferred to a tertiary care institution for HCT consultation and potentially curative therapy.\nImagingp\nas clinically\nindicated:\neg, C/A/P\nCT, chest\nCT, A/P\nMRI, PET/\nCT, or PET/\nMRI (skull\nbase to\nmid-thigh)\nSurveillance\n(LCOC-B)\nFollow path for complete\nclinical response (LCOC-14)\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.", "section": "Malignant Germ Cell Tumors", "page_from": 28, "page_to": 28, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "b84ff01216444b9482a9f78d022cadadff45fcbbd34b0901bce8355af890039e"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000089", "text": "PLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "Malignant Germ Cell Tumors", "page_from": 28, "page_to": 28, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "5e18f3d122f5f5c0bf62f64f178763607a64102384a3a5517f96df1222be28d4"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000090", "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nMalignant Germ Cell Tumors\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nLCOC-14\nMONITORING/FOLLOW-UP\nAFTER ADJUVANT TREATMENT\nTHERAPY FOR RECURRENT/\nPERSISTENT DISEASEff\nPATHOLOGIC\nDIAGNOSISa\nAny stage\nembryonal tumorii\nor\nAny stage\nendodermal sinus\ntumor (yolk sac\ntumor)ii\nor\nStage II–IV\ndysgerminoma\nor\nStage I, grade 2\nor 3 or Stage II–IV\nimmature teratoma\nor\nAny stage\nnongestational\nchoriocarcinoma\nAbnormal\nmarkers,\ndefinitive\nrecurrent\ndisease\nSecond-line\nchemotherapyee (category 2B)\nor\nHigh-dose chemotherapyll + HCT\n(category 2B)\nor\nConsider surgery for select patients\nObserve\n(LCOC-B)\nComplete clinical\nresponse\nLCOC-A\nComplete\nclinical\nresponse\nIncomplete\nclinical\nresponse\na WHO Histologic Classification (OV-E).\nee See Principles of Systemic Therapy (OV-C) and Systemic Therapy Regimens for Malignant Germ Cell/Sex Cord-Stromal Tumors (LCOC-A).", "section": "Malignant Germ Cell Tumors", "page_from": 29, "page_to": 29, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "260177c40ebca323af04a39d792c92b2ef83a3dc36ac31cc34966c1cd59c6863"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000091", "text": "clinical\nresponse\na WHO Histologic Classification (OV-E).\nee See Principles of Systemic Therapy (OV-C) and Systemic Therapy Regimens for Malignant Germ Cell/Sex Cord-Stromal Tumors (LCOC-A).\nff Localized RT can be considered to palliate symptoms and/or for oligometastatic disease.\nii Pediatric/adolescent patients with the following clinical presentations may consider observation or chemotherapy as treatment options: stage IA, IB dysgerminoma;\nstage IA, grade 1 immature teratoma; stage IA embryonal carcinomas; or stage IA yolk sac tumors. Consultation with a pediatric oncologist for pediatric/adolescent\npatients is recommended.\nll High-dose chemotherapy regimens vary among institutions. Some patients are potentially curable with HCT. Patients with potentially curable recurrent germ cell\ndisease should be referred to a tertiary care institution for HCT consultation and potentially curative therapy.\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.", "section": "Malignant Germ Cell Tumors", "page_from": 29, "page_to": 29, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "fad03c83b989d193389aacada15101dfd68b831d2052aff8366cb712903b909a"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000092", "text": "PLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "Malignant Germ Cell Tumors", "page_from": 29, "page_to": 29, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "5e18f3d122f5f5c0bf62f64f178763607a64102384a3a5517f96df1222be28d4"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000093", "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nMalignant Germ Cell/Sex Cord-Stromal Tumors\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nLCOC-A\nSYSTEMIC THERAPY REGIMENSa\nMALIGNANT GERM CELL/SEX CORD-STROMAL TUMORS\na See Principles of Systemic Therapy (OV-C) and see Discussion for references.\nb High-dose chemotherapy regimens vary among institutions. Some patients are\npotentially curable with HCT. Patients with potentially curable recurrent germ cell\ndisease should be referred to a tertiary care institution for HCT consultation and\npotentially curative therapy.\nc WHO Histologic Classification (OV-E).\nd Recommend pulmonary function test if considering bleomycin.\ne Consultation with a pediatric oncologist for pediatric/adolescent patients is\nrecommended.\nMALIGNANT SEX CORD-STROMAL TUMORSa,c\nPrimary\nTherapy\nPreferred Regimens\n• Paclitaxel/carboplatin\nOther Recommended Regimens\n• Etoposide/cisplatin (EP)", "section": "NCCN Guidelines Index", "page_from": 30, "page_to": 30, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "f9ac454458c3533a9ed4f3130f917dd18486855e8a45ff97b4da764866900228"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000094", "text": "recommended.\nMALIGNANT SEX CORD-STROMAL TUMORSa,c\nPrimary\nTherapy\nPreferred Regimens\n• Paclitaxel/carboplatin\nOther Recommended Regimens\n• Etoposide/cisplatin (EP)\nUseful in Certain Circumstances\n• BEP (category 2B)d\nRecurrence\nTherapy\nPreferred Regimens\n• Paclitaxel/carboplatin\nOther Recommended Regimens\n• EP, if not previously used\n• Paclitaxel/ifosfamide\n• Docetaxel\n• Paclitaxel\n• Supportive care only (See NCCN Supportive Care Guidelines)\n• Targeted therapy: Bevacizumab (single agent)\nUseful in Certain Circumstances\n• Aromatase inhibitors (ie, anastrozole, exemestane,\nletrozole)\n• Leuprolide acetate or goserelin acetate (for granulosa cell\ntumors)\n• Tamoxifen\n• BEP (category 2B),d if not previously used\n• VAC (category 2B)\nMALIGNANT GERM CELL TUMORSa,b,c\nPrimary\nTherapy\nPreferred Regimens\n• BEP (bleomycin, etoposide, cisplatin)d\n\u0017Bleomycin 30 units IV per week plus\netoposide 100 mg/m2 IV daily on days\n1–5 plus cisplatin 20 mg/m2 IV daily on\ndays 1–5; repeat every 21 days for 3\ncycles for good risk (category 2B), or 4\ncycles for poor risk.\nOther Recommended Regimens\n• None\nUseful in Certain Circumstances", "section": "NCCN Guidelines Index", "page_from": 30, "page_to": 30, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "cddda5652de3ef277e5694d9bdea0301efea080fcba2d4f4023c567817eff945"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000095", "text": "days 1–5; repeat every 21 days for 3\ncycles for good risk (category 2B), or 4\ncycles for poor risk.\nOther Recommended Regimens\n• None\nUseful in Certain Circumstances\n• Etoposide/carboplatina,e (for select patients with stage II–III resected dysgerminoma for whom minimizing\ntoxicity is critical)\n\u0017Carboplatin 400 mg/m2 IV on day 1 plus etoposide 120 mg/m2 IV on days 1, 2, and 3 every 28 days for 3\ncycles.\nRecurrence\nTherapy\nPreferred Regimens\n(Potentially curative)\n• High-dose chemotherapyb\n• TIP (paclitaxel, ifosfamide, cisplatin)\nOther Recommended Regimens\n(Palliative only)\n• Etoposide/cisplatin (EP), if not\npreviously used\n• Docetaxel\n• Docetaxel/carboplatin\n• Etoposide (oral)\n• Etoposide/ifosfamide/cisplatin (VIP)\n• Gemcitabine/paclitaxel/oxaliplatin\n• Gemcitabine/oxaliplatin\n• Paclitaxel\n• Paclitaxel/carboplatin\n• Paclitaxel/gemcitabine\n• Paclitaxel/ifosfamide\n• Pembrolizumab (if microsatellite\ninstability-high [MSI-H]/mismatch\nrepair deficient [dMMR] or tumor\nmutational burden-high [TMB-H])\n• VeIP (vinblastine, ifosfamide,\ncisplatin)\n• VAC (vincristine,\ndactinomycin,\ncyclophosphamide)\n• Supportive care (See NCCN\nSupportive Care Guidelines)", "section": "NCCN Guidelines Index", "page_from": 30, "page_to": 30, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "0eb9843ccdb1b1df27ec10a23493b58ee2b7308b1da7b522d847d6395659ae25"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000096", "text": "mutational burden-high [TMB-H])\n• VeIP (vinblastine, ifosfamide,\ncisplatin)\n• VAC (vincristine,\ndactinomycin,\ncyclophosphamide)\n• Supportive care (See NCCN\nSupportive Care Guidelines)\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "NCCN Guidelines Index", "page_from": 30, "page_to": 30, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "7334cd84a3f439d8de6d365cd85364a1e54dc3a7a78f82248dbe1bc296930958"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000097", "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nMalignant Germ Cell/Sex Cord-Stromal Tumors\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nMalignant Sex Cord-Stromal Tumorsc\n0–2 Years\nAfter 2 Years\nPhysical exam\nAs clinically indicated based on stage\n(ie, 6–12 mo if early-stage, low-risk disease; 4–6 mo if\nhigh-risk disease)\nAs clinically indicated based on stage\n(ie, 6–12 mo if early-stage, low-risk disease; 4–6 mo if\nhigh-risk disease)\nSerum tumor markersb\n• Testing as clinically indicated, if applicable\n• If done, frequency based on stage (ie, 6–12 mo if\nearly-stage, low-risk disease; 4–6 mo if high-risk disease)\n• Testing as clinically indicated, if applicable\n• If done, frequency based on stage (ie, 6–12 mo if\nearly-stage, low-risk disease; 4–6 mo if high-risk disease)\nImagingd\nReserved for patients with symptoms, elevated biomarkers,\nor suspicious findings on physical exam", "section": "NCCN Guidelines Index", "page_from": 31, "page_to": 31, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "306d4d1ebffd36e2e4b673d7458b380dee36c6262d38ddc1c9a8cad42c39e7bb"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000098", "text": "early-stage, low-risk disease; 4–6 mo if high-risk disease)\nImagingd\nReserved for patients with symptoms, elevated biomarkers,\nor suspicious findings on physical exam\nReserved for patients with symptoms, elevated biomarkers,\nor suspicious findings on physical exam\na Only for those patients who have a residual ovary.\nb See OV-1 for markers.\nc Salani R, Khanna N, Frimer M, et al. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of\nGynecologic Oncology (SGO) recommendations. Gynecol Oncol 2017;146:3-10.\nd Chest x-ray, C/A/P CT, MRI, PET/CT, or PET; with contrast unless contraindicated.\nMalignant Germ Cell Tumors\nYear 1\nYear 2\nYear 3\nYears 4–5\nAfter 5 Years\nClinical evaluation\nEvery 3 mo\nEvery 3 mo\nEvery 6 mo\nEvery 12 mo\nEvery 12 mo\nPelvic USa\nEvery 3 mo\nEvery 3 mo\nEvery 6 mo\n--\n--\nTumor markersb\nEvery 2 mo\nEvery 3 mo\nEvery 6 mo\nEvery 12 mo\nEvery 12 mo\nup to 10 y\nChest x-ray\n--\n--\n--\nEvery 6 mo\nAs clinically indicated\nC/A/P CT\nEvery 3 mo\nEvery 3 mo\nEvery 6–12 mo\nAs clinically indicated\nAs clinically indicated\nSURVEILLANCE\nMALIGNANT GERM CELL/SEX CORD-STROMAL TUMORS\nLCOC-B", "section": "NCCN Guidelines Index", "page_from": 31, "page_to": 31, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "79b73c29d36a463541439e2c81f1d9864e2b8c936387f5713fbb25ce14d46ec8"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000099", "text": "--\n--\nEvery 6 mo\nAs clinically indicated\nC/A/P CT\nEvery 3 mo\nEvery 3 mo\nEvery 6–12 mo\nAs clinically indicated\nAs clinically indicated\nSURVEILLANCE\nMALIGNANT GERM CELL/SEX CORD-STROMAL TUMORS\nLCOC-B\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "NCCN Guidelines Index", "page_from": 31, "page_to": 31, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "907a1375080089ec60aa26727dedf54f15564cbf83f41250f838770831c35bc4"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000100", "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNCCN Guidelines Version 3.2025\nOvarian Cancer/Fallopian Tube Cancer/Primary\nPeritoneal Cancer\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nOV-A\n1 OF 4\nPRINCIPLES OF SURGERY1\nGeneral Considerations\n• It is recommended that a gynecologic oncologist perform the appropriate surgery.\n• An open laparotomy including a vertical midline abdominal incision should be used in most patients with a suspected malignant ovarian/\nfallopian tube/primary peritoneal neoplasm in whom a surgical staging procedure, a primary debulking procedure, an interval debulking\nprocedure, or secondary cytoreduction is planned.\n\u0017For select patients, a minimally invasive surgical approach may be used by an experienced surgeon to manage early-stage disease.\nLaparoscopy may be useful to evaluate whether optimal cytoreduction can be achieved in patients with newly diagnosed advanced-stage\nor recurrent disease.", "section": "Peritoneal Cancer", "page_from": 32, "page_to": 32, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "af948c240f01b062181e07b50fea8696557481403443175b3c241654d6ef38db"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000101", "text": "Laparoscopy may be useful to evaluate whether optimal cytoreduction can be achieved in patients with newly diagnosed advanced-stage\nor recurrent disease.\n\u0017Minimally invasive techniques can be used for select patients for interval debulking procedures. Patients who are unable to be optimally\ndebulked using minimally invasive techniques should be converted to an open procedure.\n• Intraoperative pathologic evaluation with frozen sections may assist in management.\n• Prior to surgery for ovarian cancer, counsel patients about port placement if intraperitoneal (IP) chemotherapy is being considered.\nOperative Reports\n• Surgeons should describe the following in the operative report:\n\u0017Extent of initial disease before debulking pelvis, mid-abdomen, or upper abdomen (cutoffs: pelvic brim to lower ribs).\n\u0017Amount of residual disease in the same areas after debulking.\n\u0017Complete or incomplete resection; if incomplete, indicate the size of the major lesion and total number of lesions. Indicate if miliary or\nsmall lesions.\nContinued\n1 Fleming GF, Seidman J, Yemelyanova A, and Lengyl E. Epithelial Ovarian Cancer. In: Chi DS, Berchuck A, Dizon D, et al (eds). Principles and Practice of Gynecologic", "section": "Peritoneal Cancer", "page_from": 32, "page_to": 32, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "3e8b5d62aade9002615d79a9a1e5a5c3bfcaaddc789c52618016e72be3c38aab"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000102", "text": "small lesions.\nContinued\n1 Fleming GF, Seidman J, Yemelyanova A, and Lengyl E. Epithelial Ovarian Cancer. In: Chi DS, Berchuck A, Dizon D, et al (eds). Principles and Practice of Gynecologic\nOncology, 7th ed, Philadelphia, Lippincott Williams & Wilkins, 2017:611-705.\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "Peritoneal Cancer", "page_from": 32, "page_to": 32, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "498d1d0766d4aa0ac368f2afda9524be453ef5f57b6f21a077c481922deb966b"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000103", "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNCCN Guidelines Version 3.2025\nOvarian Cancer/Fallopian Tube Cancer/Primary\nPeritoneal Cancer\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nNewly Diagnosed Invasive Epithelial Ovarian Cancer Apparently Confined to the Ovaries, Fallopian Tubes, and Uterus (apparent stage IA–IIA)\nIn general, every effort should be made during a primary cytoreduction procedure to achieve maximum cytoreduction of all pelvic disease and\nto evaluate for occult disease in the upper abdomen or retroperitoneum.\n• On entering the abdomen, aspiration of ascites or peritoneal lavage should be performed for peritoneal cytologic examinations.\n• All peritoneal surfaces should be visualized, and any peritoneal surface or adhesion suspicious for harboring metastasis should be\nselectively excised or biopsied. In the absence of any suspicious areas, random peritoneal biopsies should be taken from the pelvis,", "section": "Peritoneal Cancer", "page_from": 33, "page_to": 33, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "7f1f3341b1e98b2e09c077b6910f9e6f13844c5bccd9e915ed499667372ca880"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000104", "text": "selectively excised or biopsied. In the absence of any suspicious areas, random peritoneal biopsies should be taken from the pelvis,\nparacolic gutters, and undersurfaces of the diaphragm (diaphragm scraping for Papanicolaou stain is an acceptable alternative).\n• BSO and hysterectomy should be performed with every effort to keep an encapsulated mass intact during removal.\n• For selected patients desiring to preserve fertility, USO or BSO with uterine preservation may be considered. Uterine preservation allows for\npotential future assisted reproductive approaches.\n• Omentectomy should be performed.\n• Para-aortic lymph node dissection should be performed by stripping the nodal tissue from the vena cava and the aorta bilaterally to at least\nthe level of the inferior mesenteric artery and preferably to the level of the renal vessels.\n• The preferred method of dissecting pelvic lymph nodes is bilateral removal of lymph nodes overlying and anterolateral to the common iliac\nvessel, overlying and medial to the external iliac vessel, overlying and medial to the hypogastric vessels, and from the obturator fossa at a\nminimum anterior to the obturator nerve.2", "section": "Peritoneal Cancer", "page_from": 33, "page_to": 33, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "210f00307533044058ff8539b51271edb235b666497ca9a1f646c1d731c4271f"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000105", "text": "vessel, overlying and medial to the external iliac vessel, overlying and medial to the hypogastric vessels, and from the obturator fossa at a\nminimum anterior to the obturator nerve.2\nNewly Diagnosed Invasive Epithelial Ovarian Cancer Involving the Pelvis and Upper Abdomen (stage >IIB)\nIn general, every effort should be made during a primary cytoreduction procedure to achieve maximum cytoreduction of all abdominal, pelvic,\nand retroperitoneal disease. Residual disease <1 cm defines optimal cytoreduction; however, maximal effort should be made to remove all\ngross disease since this offers superior survival outcomes.3\n• Aspiration of ascites (if present) should be performed for peritoneal cytologic examinations. All involved omentum should be removed.\n• Suspicious and/or enlarged nodes, identified on preoperative imaging or during surgical exploration, should be resected, if possible.\nResection of clinically negative nodes is not required.4\n• Procedures that may be considered for optimal surgical cytoreduction (in all stages) include bowel resection and/or appendectomy, stripping", "section": "Peritoneal Cancer", "page_from": 33, "page_to": 33, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "62fec6a7514031b515d1744eb1aef554870e51a7bb6b1873961be64f05e9927c"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000106", "text": "Resection of clinically negative nodes is not required.4\n• Procedures that may be considered for optimal surgical cytoreduction (in all stages) include bowel resection and/or appendectomy, stripping\nof the diaphragm or other peritoneal surfaces, splenectomy, partial cystectomy and/or ureteroneocystostomy, partial hepatectomy, partial\ngastrectomy, cholecystectomy, and/or distal pancreatectomy.\n• Select patients with low-volume residual disease after surgical cytoreduction for invasive epithelial ovarian or peritoneal cancer are potential\ncandidates for IP therapy. In these patients, consideration should be given to placement of IP catheter with initial surgery.\nOV-A\n2 OF 4\nPRINCIPLES OF SURGERY1\n1 Fleming GF, Seidman J, Yemelyanova A, and Lengyl E. Epithelial Ovarian Cancer. In: Chi DS, Berchuck A, Dizon D, et al (eds). Principles and Practice of Gynecologic\nOncology, 7th ed, Philadelphia, Lippincott Williams & Wilkins, 2017:611-705.\n2 Whitney CW, Spirtos N. Gynecologic Oncology Group Surgical Procedures Manual. Philadelphia: Gynecologic Oncology Group; 2010.", "section": "Peritoneal Cancer", "page_from": 33, "page_to": 33, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "a362594c7afed6342a010d565fc5b1a25bf60e5b32a9cecaa917efce653b40df"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000107", "text": "2 Whitney CW, Spirtos N. Gynecologic Oncology Group Surgical Procedures Manual. Philadelphia: Gynecologic Oncology Group; 2010.\n3 Chi DS, Eisenhauer EL, Zivanovic O, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm.\nGynecol Oncol 2009;114:26-31.\n4 Harter P, Sehouli J, Lorusso D, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med 2019;380:822-832.\nContinued\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "Peritoneal Cancer", "page_from": 33, "page_to": 33, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "f92ea86587b2cfda267b712f04b85fd0b8c73030a9eaf9247c22174b43e57233"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000108", "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNCCN Guidelines Version 3.2025\nOvarian Cancer/Fallopian Tube Cancer/Primary\nPeritoneal Cancer\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nInterval Debulking Surgery After Neoadjuvant Chemotherapy of\nInvasive Epithelial Ovarian Cancer\nAs with a primary debulking procedure, every effort should be made\nto achieve maximum cytoreduction during an interval debulking\nprocedure. Maximal effort should be made to remove all gross\ndisease in the abdomen, pelvis, and retroperitoneum. Consultation\nwith a gynecologic oncologist is recommended.\n• IDS, including completion hysterectomy and BSO with staging,\nshould be performed after 3–4 cycles of neoadjuvant chemotherapy\nfor patients with a response to chemotherapy or stable disease.\nAlternate timing of surgery has not been prospectively evaluated but\nmay be considered based on individual patient-centered factors.", "section": "Peritoneal Cancer", "page_from": 34, "page_to": 34, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "f51cf1ee5f51b8730b20ab9b08430971b887bda34873d15b5ae3203d8c6eacf7"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000109", "text": "for patients with a response to chemotherapy or stable disease.\nAlternate timing of surgery has not been prospectively evaluated but\nmay be considered based on individual patient-centered factors.\n• HIPEC with cisplatin (100 mg/m2) can be considered at the time of\nIDS for stage III disease. HIPEC can also be considered for suitable\nstage IV patients (category 2B) who have had a favorable response\nto neoadjuvant therapy both intraperitoneally and extraperitoneally,\nor in whom stage IV disease sites have completely resolved (eg,\nresolution of malignant pleural effusion) or are now deemed\nresectable. Sodium thiosulfate may be administered at the start\nof perfusion, followed by a continuous infusion, to allow for renal\nprotection during HIPEC.\n• All peritoneal surfaces should be visualized, and any peritoneal\nsurface or adhesion suspicious for harboring metastasis should be\nselectively excised or biopsied.\n• An omentectomy should be performed.\n• While systematic lymphadenectomy of clinical-negative nodes is\nnot recommended, suspicious and/or enlarged nodes should be\nresected, if possible.\n• Procedures that may be considered for optimal surgical debulking", "section": "Peritoneal Cancer", "page_from": 34, "page_to": 34, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "5216c6a1d4ff3a4464f3263d0c1226a98efab8637f4e28538b8b764f61c9248a"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000110", "text": "not recommended, suspicious and/or enlarged nodes should be\nresected, if possible.\n• Procedures that may be considered for optimal surgical debulking\ninclude bowel resection and/or appendectomy, stripping of the\ndiaphragm or other peritoneal surfaces, splenectomy, partial\ncystectomy and/or ureteroneocystostomy, partial hepatectomy,\npartial gastrectomy, cholecystectomy, and/or distal pancreatectomy.\nRisk-Reducing Salpingo-Oophorectomy (RRSO) Protocol\n• For information on when RRSO is indicated, see NCCN Guidelines\nfor Genetic/Familial High-Risk Assessment: Breast, Ovarian,\nPancreatic, and Prostate.\n• Perform minimally invasive laparoscopic surgery.\n• Survey upper abdomen, bowel surfaces, omentum, appendix (if\npresent), and pelvic organs.\n• Biopsy any abnormal peritoneal findings.\n• Obtain pelvic washing for cytology (50 cc normal saline instilled and\naspirated immediately).\n• Perform total BSO, removing 2 cm of proximal ovarian vasculature/\nIP ligament, all tube up to the cornua, and all peritoneum\nsurrounding the ovaries and tubes, especially peritoneum\nunderlying areas of adhesion between tube and/or ovary and the\npelvic sidewall.5", "section": "Peritoneal Cancer", "page_from": 34, "page_to": 34, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "802f9b8747b3b51c8b77edc40104f624106ea39a173c98ef9231a699e4b96604"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000111", "text": "IP ligament, all tube up to the cornua, and all peritoneum\nsurrounding the ovaries and tubes, especially peritoneum\nunderlying areas of adhesion between tube and/or ovary and the\npelvic sidewall.5\n• Engage in minimal instrument handling of the tubes and ovaries to\navoid traumatic exfoliation of cells.5\n• Both ovaries and tubes should be placed in an endobag for retrieval\nfrom the pelvis.\n• Both ovaries and tubes should be processed by sectioning and\nextensively examining the fimbriated end (SEE-FIM) protocol.6\n• If occult malignancy or serous tubal intraepithelial carcinoma (STIC)\nis identified, provide referral to a gynecologic oncologist.\n• The prevention benefits of salpingectomy alone are not yet proven.\nIf considered, the fallopian tube from the fimbria to its insertion into\nthe uterus should be removed. In addition, the fallopian tube should\nbe processed and assessed as described above. The concern for\nrisk-reducing salpingectomy alone is that patients are still at risk for\ndeveloping ovarian cancer. In addition, in premenopausal patients,\noophorectomy reduces the risk of developing breast cancer but the\nmagnitude is uncertain. See NCCN Guidelines for Genetic/Familial", "section": "Peritoneal Cancer", "page_from": 34, "page_to": 34, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "53fd6219d5bbb846f4ffc6e5c211c6b8c5cc98fe6fe0152439ce71eaa16b1e3a"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000112", "text": "developing ovarian cancer. In addition, in premenopausal patients,\noophorectomy reduces the risk of developing breast cancer but the\nmagnitude is uncertain. See NCCN Guidelines for Genetic/Familial\nHigh-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate.\nPRINCIPLES OF SURGERY1\n1 Fleming GF, Seidman J, Yemelyanova A, and Lengyl E. Epithelial Ovarian Cancer. In: Chi DS, Berchuck A, Dizon D, et al (eds). Principles and Practice of Gynecologic\nOncology, 7th ed, Philadelphia, Lippincott Williams & Wilkins, 2017:611-705.\n5\u0007 Powell CB, Chen LM, McLennan J, et al. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using\na standardized surgical-pathological protocol. Int J Gynecol Cancer 2011;21:846-851.\n6 Mingels MJ, van Ham MA, de Kievit IM, et al. Müllerian precursor lesions in serous ovarian cancer patients: using the SEE-Fim and SEE-End protocol. Mod Pathol\n2014;27:1002-1013.\nOV-A\n3 OF 4\nContinued\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.", "section": "Peritoneal Cancer", "page_from": 34, "page_to": 34, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "2ae9f3a64505dc450a39ed99898f79805176ead159182b1d3f6066ad6b0b04c3"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000113", "text": "Continued\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "Peritoneal Cancer", "page_from": 34, "page_to": 34, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "63d828dec5118f88aaf384da90b30448326d229256786c0178594bb9391e8c7c"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000114", "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNCCN Guidelines Version 3.2025\nOvarian Cancer/Fallopian Tube Cancer/Primary\nPeritoneal Cancer\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nSpecial Circumstances\n• Fertility-sparing surgery:\n\u0017Fertility-sparing surgery with USO (preserving the uterus and contralateral ovary) or BSO (preserving the uterus) can be considered for\npatients with apparent early-stage disease and/or low-risk tumors (early-stage invasive epithelial tumors, LMP lesions, malignant germ cell\ntumors, mucinous tumors, or malignant sex cord-stromal tumors) who wish to preserve fertility. Consider endometrial sampling to exclude\nsynchronous primary or hyperplasia. Refer to reproductive endocrinologist for evaluation and REI consultation as clinically indicated.\nComprehensive surgical staging should still be performed to rule out occult higher stage disease but may be omitted in pediatric,", "section": "Peritoneal Cancer", "page_from": 35, "page_to": 35, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "5263e3f0658b8f7119f73f993d96cd03e6bf6899f8156bdd9832a6f791ef8589"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000115", "text": "Comprehensive surgical staging should still be performed to rule out occult higher stage disease but may be omitted in pediatric,\nadolescent, and young adult patients with clinically apparent early-stage malignant germ cell tumors based on the pediatric surgical\nliterature.7\n• Mucinous tumors: Primary invasive mucinous tumors of the ovary are uncommon. Thus, the upper and lower GI tract should be carefully\nevaluated to rule out an occult GI primary with ovarian metastases, and an appendectomy need only be performed in patients with a\nsuspected or confirmed mucinous ovarian neoplasm if it appears to be abnormal. A normal appendix does not require surgical resection in\nthis setting. If mucinous histology is confirmed by intraoperative frozen section analysis and there are no suspicious lymph nodes, consider\nomitting lymphadenectomy.\n• Ovarian borderline epithelial (LMP) tumors: Although data show upstaging with lymphadenectomy, other data show that lymphadenectomy\ndoes not affect overall survival. However, omentectomy and multiple biopsies of peritoneum (the most common sites of peritoneal implants)\nmay upstage patients in approximately 30% of cases and may affect prognosis.", "section": "Peritoneal Cancer", "page_from": 35, "page_to": 35, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "0f468ccd5309a96adec20433d56ef780401085d055656facf7429d5b46761a19"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000116", "text": "may upstage patients in approximately 30% of cases and may affect prognosis.\n• Secondary cytoreduction: A secondary cytoreduction procedure can be considered in patients with recurrent ovarian cancer who develop\na recurrence more than 6 months since completion of initial chemotherapy, have a good performance status, have no ascites, and have\nan isolated focus or limited foci of disease amenable to complete resection. In addition to preoperative imaging, laparoscopy may be used\nto determine if complete resection can be achieved. Secondary cytoreduction can be performed with either open or minimally invasive\napproaches. Consider using validated scoring methods to assess suitability for secondary cytoreduction.\nAncillary Palliative Surgical Procedures8\nThese procedures may be appropriate in select patients:\n• Paracentesis/indwelling peritoneal catheter\n• Thoracentesis/pleurodesis/video-assisted thoracoscopy/indwelling pleural catheter\n• Ureteral stents/nephrostomy\n• Gastrostomy tube/intestinal stents/surgical relief of intestinal obstruction\nPRINCIPLES OF SURGERY1", "section": "Peritoneal Cancer", "page_from": 35, "page_to": 35, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "1e05482b512ada323f516d61dbfb617a2aa59221a543c4bb50ed84c5406fc3e7"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000117", "text": "• Ureteral stents/nephrostomy\n• Gastrostomy tube/intestinal stents/surgical relief of intestinal obstruction\nPRINCIPLES OF SURGERY1\n1 Fleming GF, Seidman J, Yemelyanova A, and Lengyl E. Epithelial Ovarian Cancer. In: Chi DS, Berchuck A, Dizon D, et al (eds). Principles and Practice of Gynecologic\nOncology, 7th ed, Philadelphia, Lippincott Williams & Wilkins, 2017:611-705.\n7 Billmire D, Vinocur C, Rescorla F, et al. Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study.\nJ Pediatr Surg 2004;39:424-429.\n8 Decisions on the use of ancillary procedures should be made in conjunction with a gynecologic oncology surgeon or a practitioner familiar with ovarian cancer patterns\nof recurrence.\nOV-A\n4 OF 4\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.", "section": "Peritoneal Cancer", "page_from": 35, "page_to": 35, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "c1642d1f3c06601b83d61f1f2b8668128350681f7b62bb035725a54415b38138"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000118", "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNCCN Guidelines Version 3.2025\nOvarian Cancer/Fallopian Tube Cancer/Primary\nPeritoneal Cancer\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nOV-B\n1 OF 3\nPRINCIPLES OF PATHOLOGY\nContinued\nGeneral\n• The complete histologic classification from the WHO is included in\nthe NCCN Guidelines (WHO Histologic Classification on OV-E).1 The\nWHO pathology manual is also a useful resource.1\n• Most ovarian cancers, including the LCOC, are diagnosed after\npathologic analysis of a biopsy or surgical specimen. Fine-needle\naspiration (FNA) should be avoided for diagnosis of ovarian cancer\nin patients with presumed early-stage disease to prevent rupturing\nthe cyst and spilling malignant cells into the peritoneal cavity.\nHowever, FNA may be necessary in patients with bulky disease who\nare not candidates for primary debulking.2,3\n• Both primary peritoneal and fallopian tube cancers are usually", "section": "Peritoneal Cancer", "page_from": 36, "page_to": 36, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "9e23220b811163f8272887509f95921ee565b576e4a901290a1d652a238f74a8"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000119", "text": "However, FNA may be necessary in patients with bulky disease who\nare not candidates for primary debulking.2,3\n• Both primary peritoneal and fallopian tube cancers are usually\ndiagnosed postoperatively (if there is no major involvement of the\novary) or preoperatively (if there is a biopsy and the patient has\nalready had a bilateral salpingo-oophorectomy). Primary peritoneal\nand fallopian tube cancers are treated in the same manner as\nepithelial ovarian cancer.\n• The CAP protocol is a useful tool for pathology reports.4\nPathologic assessment should include:\n\u0017Elements from CAP protocol4:\n ◊Tumor site(s) (eg, ovary, fallopian tube, or primary peritoneum)\n ◊Tumor size(s)\n ◊Other tissue/organ involvement\n ◊Ovarian/fallopian tumors: surface involvement (present/absent/\ncannot determine), specimen integrity (capsule/serosa intact/\nfractured/fragmented)\n ◊Histologic type and grade\n ◊Extension and/or implants (if sampled/identified)\n ◊Cytology: peritoneal or ascitic fluid or washings/pleural fluid\n ◊Lymph nodes: number and location of nodes examined, size of\nlargest metastatic deposits\n ◊STIC, endometriosis (particularly if in continuity with", "section": "Peritoneal Cancer", "page_from": 36, "page_to": 36, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "7d60547ab7d98459b6c7a749315b819769d6a007b2da5dcb3f1ca0d4d7b42e3e"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000120", "text": "◊Lymph nodes: number and location of nodes examined, size of\nlargest metastatic deposits\n ◊STIC, endometriosis (particularly if in continuity with\nendometrioid or clear cell carcinoma), and/or endosalpingiosis\n ◊Staging information (FIGO and TNM)\n• Tumor molecular analyses\n\u0017In the upfront setting, choice of somatic testing should, at a\nminimum, optimize identification of molecular alterations that\ncan inform use of interventions that have demonstrated benefit in\nthis setting, including BRCA1/2, loss of heterozygosity (LOH), or\nhomologous recombination deficiency (HRD) status in the absence\nof a germline BRCA mutation.\n\u0017In the recurrence setting, tumor molecular analysis is\nrecommended to include, as appropriate, tests to identify potential\nbenefit from targeted therapeutics that have tumor-specific or\ntumor-agnostic benefit including, but not limited to, HER2 status\n(by IHC), BRCA1/2, HRD status, microsatellite instability (MSI),\nmismatch repair (MMR), tumor mutational burden (TMB), BRAF,\nFRα (FOLR1), RET, and NTRK if prior testing did not include\nthese markers. More comprehensive testing may be particularly\nimportant in less common histologies with limited approved", "section": "Peritoneal Cancer", "page_from": 36, "page_to": 36, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "7e42f1a6505702a66b15e28bfc933a8d91d4d6b17d4acf4efbeb54780bd5f9f5"}
{"doc_id": "nccn_ovariancancer_v3_2025__v00000000", "chunk_id": "000121", "text": "FRα (FOLR1), RET, and NTRK if prior testing did not include\nthese markers. More comprehensive testing may be particularly\nimportant in less common histologies with limited approved\ntherapeutic options. It is recommended that such testing be\nperformed on the most recent available tumor tissue.\n\u0017Molecular analyses may be performed on circulating tumor\nDNA (ctDNA or liquid biopsy) when tissue-based analysis is not\nclinically feasible.\n\u0017Validated molecular testing should be performed in a CLIA-\napproved facility.", "section": "Peritoneal Cancer", "page_from": 36, "page_to": 36, "display_name": "NCCN_OvarianCancer_v3.2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "ff37c4643ea7eaa08d2a3d488ce09ff440748f9a7eb33b947c6c1b780880e47a"}
